pharmacokinetics, pharmacodynamics, pharmacogenomics, drug transporters, drug metabolism, drug-drug interactions, biopharmaceutics, drug delivery, enzymes and transporters, biopharmaceutics classification system (BCS), biopharmaceutics drug disposition classification system (BDDCS)

Professional background

Biography

Dr. Benet, Professor and former Chairman (1978-1998), Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California, San Francisco, received his A.B. (English), B.S. (Pharmacy), M.S. from the University of Michigan and Ph.D. from the University of California. He has received nine honorary doctorates: Uppsala University, Sweden (Pharm.D., 1987), Leiden University, The Netherlands (Ph.D., 1995), University of Illinois at Chicago (D.Sc., 1997), Philadelphia College of Pharmacy and Science (D.Sc., 1997), Long Island University (D.Sc., 1999), University of Athens, Greece (Ph.D., 2005), Catholic University of Leuven, Belgium (Ph.D., 2010), University of Michigan (D.Sc., 2011) and University of Lisbon, Portugal (Ph.D., 2016). His research interests, more than 620 publications, 7 books and 12 patents are in the areas of pharmacokinetics, biopharmaceutics, drug delivery and pharmacodynamics. Dr. Benet is listed by Clarivate Analytics as one of the most highly cited pharmacologists worldwide with his published peer-reviewed papers cited over 33,000 times, while Google Scholar credits him with over 50,000 citations. His most recent work has addressed the deficiencies of in vitro-in vivo extrapolation (IVIVE) and different approaches to advancing our understanding and prediction of clearance processes. Dr. Benet was a Founder/Editor of the JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS (1973-98) and Associate Editor of PHARMACOLOGY AND THERAPEUTICS (1995-2000). He presently serves a member of the Editorial boards of PHARMACOLOGY and AAPS JOURNAL. He is a Fellow of the American Association for the Advancement of Science (AAAS), the American Association of Pharmaceutical Scientists (AAPS), the American College of Clinical Pharmacology (ACCP) and the Controlled Release Society (CRS). In 1982, Dr. Benet received the APhA Academy of Pharmaceutical Sciences (APS) Research Achievement Award in Pharmaceutics and the University of Michigan, College of Pharmacy, Distinguished Alumnus Award. In 1985, he served as President of APS. During 1986, Dr. Benet was a Founder and first President of the AAPS. In 1987, Dr. Benet was elected to membership in the National Academy of Medicine (NAM) of the U.S. National Academy of Sciences. In 1988, he received the ACCP Distinguished Service Award and in 1989, the AAPS Distinguished Pharmaceutical Scientist Award. In 1990, he was the recipient of the Rho Chi Lecture Award, and the UCSF Long Teaching Award, while in 1991, he received the Volwiler Research Achievement Award of the American Association of Colleges of Pharmacy (AACP). In 1993-94, he served as AACP President. In 1995, he received the Rawls-Palmer Progress in Medicine Award of the American Society for Clinical Pharmacology and Therapeutics (ASCPT); in 1996, the AAPS Distinguished Service Award; and in 2000 the APhA Takeru Higuchi Research Prize and the AAPS Wurster Research Award in Pharmaceutics. In 2001 he was awarded the Høst-Madsen Medal of the International Pharmaceutical Federation (FIP) and the UCSF Outstanding Faculty Mentorship Award (repeated in 2016). In 2004, he was awarded the Pharmaceutical Sciences World Congress Research Achievement Award and the CRS Career Achievement in Oral Drug Delivery Award. In 2007 he was selected as the UCSF Distinguished Clinical Research Lecturer; in 2010, the ASCPT Hunter Memorial Award in Therapeutics; and in 2011 the ACCP Distinguished Investigator award. In 2012, the September issue of PHARMACEUTICAL RESEARCH was dedicated in his honor and he was made an honorary member of FIP. In 2013, he was awarded the APhA Ebert Prize, the AAPS Journal Outstanding Manuscript award and the September issue of JOURNAL OF PHARMACEUTICAL SCIENCES was dedicated in his honor. In 2015 he received the ISSX North American Scientific Achievement award; in 2016 the Remington Honor Medal from the APhA, the highest honor in American Pharmacy; and in 2017 a full day symposium in his honor entitled “The Cutting Edge in Pharmaceutical Sciences—50 Years of Progress Celebrating Les Benet’s 80th Birthday” was held in conjunction with the Pharmaceutical Sciences World Congress in Stockholm, Sweden. In 2023 he received the Lifetime Achievement Award of the Frankfurt Foundation for the Quality of Medicines. Dr. Benet formerly served as Chair of the Pharmacology Study Section and the Pharmacological Sciences Review Committee for the NIH, the FDA CBER Peer Review Committee, the FDA Expert Panel on Individual Bioequivalence, the Board of Pharmaceutical Sciences of the FIP, the Organizing Committee for the FIP Millennial World Congress of Pharmaceutical Sciences, the Congressionally mandated NAM/National Research Council (NRC) Committee on Accelerating the Research, Development and Acquisition of Medical Countermeasures Against Biological Warfare Agents and the FIP Foundation for Education and Research and as a member of the FDA Science Board, the FDA Generic Drugs Advisory Committee and the NRC Biodefense Standing Committee. He presently serves as Chair of the Board of Directors of Medicines360, a nonprofit pharmaceutical company, emphasizing products for women’s health. July 2023

Research keywords

Hepatocytes
Cytochrome P-450 CYP3A
Cyclosporine
biopharmaceutics
Nitroglycerin
Intestinal Absorption
Cytochrome P-450 Enzyme System
Metabolic Clearance Rate
pharmacokinetics
Microsomes, Liver
Therapeutic Equivalency
drug interactions
liver
Biological Models
Pharmaceutical Preparations

1.	Remington Honor Medal, American Pharmacists Association, 2016
2.	Doctor of Philosophy, honoris causa, University of Lisbon, Portugal, 2016
3.	William B. Abrams Lectureship, FDA/CDER and ASCPT, 2015
4.	William B. Abrams Lectureship, FDA/CDER and American Society for Clinical Pharmacology and Therapeutics, 2015
5.	North American Scientific Achievement Award, International Society for the Study of Xenobiotics, 2015
6.	"25 Top Pharmacy Professors" in USA, Medical Technology Schools, 2015
7.	Listed among "25 Top Pharmacy Professors" in the U.S.A., Medical Technology Schools, 2015
8.	Guest Professorship, Sichuan University, Sichuan Province, China, 2014-2019
9.	1 of 16 pharmacologists worldwide to be listed in both 2001 and 2014 compilations, Thompson Reuters Highly Cited Researcher, 2014
10.	Highly cited Researcher-Pharmacology, Thomson Reuters, 2014
11.	AAPS Journal Manuscript Award for the Most Outstanding Manuscript, American Association of Pharmaceutical Scientists, 2013
12.	2013 APhA-APRS Ebert Prize, American Pharmacists Association Academy of Pharmaceutical Research and Science (APhA-APRS),, 2013
13.	Busse Lecture, University of Wisconsin, 2013
14.	Invited Plenary Lecture, CPSA Shanghai 2012: From Bench to Decision Making – From Basics to Applications, Shanghai, China, 2012
15.	Honorary Member, Chinese Society of Clinical Pharmacy, Zhengzhou, China, 2012
16.	Honorary Member, International Pharmaceutical Federation, The Netherlands, 2012
17.	Invited Plenary Lecture, International Symposium on Past, Present and Future Molecular Pharmacokinetics, Tokyo, Japan, 2012
18.	Invited Keynote Lecture, NRPB – AAPS Workshop on Clinical and Diagnostic Biomarkers, Taipei, Taiwan, 2012
19.	Invited Keynote Lecture, Texas Tech University Health Science Center School of Pharmacy Research Days, Texas Tech University, 2012
20.	Visiting Professor of the First Clinical Medical College of Zhengzhou University, and the Institute, Zhengzhou University, Henan Province, China, 2012
21.	Distinguished Investigator Award, American College of Clinical Pharmacology, 40th Annual Meeting, Chicago, IL, 2011
22.	The AstraZeneca Drug Hunting Lecture, AstraZeneca Research & Development Mölndal, Sweden, 2011
23.	Invited Plenary Lecture, Symposium, Biomedical Centre, Uppsala University, Uppsala, Sweden, 2011
24.	Inaugural Albert B. Prescott Distinguished Lecture, Horace Rackham School of Graduate Studies, University of Michigan, 2011
25.	Named “National Associate”, National Research Council, 2011
26.	Gerhard Levy Distinguished Lectureship in Pharmaceutical Sciences, State University of New York at Buffalo, 2011
27.	Doctor of Science, honoris causa, University of Michigan, 2011
28.	Invited Plenary Lecture, 18th International Symposium on Microsomes and Drug Oxidations, Beijing, China, 2010
29.	Invited Plenary Lecture, 2010 Pharmaceutical Sciences World Congress and the AAPS Annual Meeting and Exposition, New Orleans,, 2010
30.	Oscar B. Hunter Memorial Award in Therapeutics, American Society for Clinical Pharmacology and Therapeutics 111th Annual Meeting, Atlanta, Georgia, 2010
31.	Doctor of Philosophy, honoris causa, Catholic University of Leuven, Leuven, Belgium, 2010
32.	Elected Fellow, Controlled Release Society, 2010
33.	Invited Keynote Lecture, The 42nd Annual Pharmaceutics Graduate Student Research Meeting (PGSRM), The Ohio State University, 2010
34.	Invited Plenary Lecture, 129th Annual Meeting of the Pharmaceutical Society of Japan, Kyoto, Japan, 2009
35.	Invited Plenary Lecture, 9th International Symposium of the Controlled Release Society Indian Chapter, Mumbai, India, 2009
36.	Nagai Foundation Tokyo Distinguished Lectureship 2008, 2008
37.	National Defense Medical Center, Taipei, 2008
38.	Invited Keynote Speaker, 100th Anniversary of School of Pharmacy, NDMC; 2008 PST & TSHP Joint International Conference, 2008
39.	Paul Ehrlich Magic-Bullet Award 2008 Lifetime Achievement, 100th Anniversary of the Nobel Prize Awarded to Paul Ehrlich, Nürnberg, Germany, 2008
40.	Invited Featured Speaker, 109th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, 2008
41.	Invited Plenary Lecture, 28th Annual Meeting of the Japanese Society for Drug Delivery Systems, Tokyo, Japan, 2008
42.	Keynote Lecture, 8th International Symposium on Advances in Technology & Business Potential of New Drug Delivery Syst, 2008
43.	Invited Plenary Lecture, Modified Release Forum, West Point, PA, 2008
44.	Chair, Scientific Advisory Board, iMED.UL (Research Institute for Medicines and Pharmaceutical Sciences) University of Lisbon, Portuga, 2008
45.	Plenary Lecture, 7th International Symposium on Advances in Technology and Business Potential of New Drug Delivery Sy, 2007
46.	Keynote Lecture, Biocomputing Day, Division of Biocomputing, School of Medicine, University of New Mexico, 2007
47.	International Honorary Member, Japan Society for the Study of Xenobiotics, Sendai, Japan, 2007
48.	Keynote Lecture, Meeting of the European Drug Absorption Network, Leuven, Belgium, 2007
49.	UCSF 7th Distinguished Clinical Research Lecturer, University of California San Francisco, 2007
50.	Graduation Speaker, University of Michigan College of Pharmacy, Ann Arbor, MI, 2007
51.	Plenary Lecture, 16th International Symposium on Microsomes and Drug Oxidation, Budapest, 2006
52.	Plenary Lecture, 4th International COE Symposium, Target Validation, Lead Optimization & Clinical Development, Tokyo, 2006
53.	Plenary Lecture, Analytica Conference 2006, Munich, Germany, 2006
54.	Plenary Lecture, Canadian Society for Pharmaceutical Sciences 9th Annual International Symposium on Pharmaceutical Sc, 2006
55.	Chair, Gordon Research Conference on Drug Metabolism, Plymouth, NH, 2006
56.	Keynote Address, Great Lakes Symposium 2006, Buffalo, NY, 2006
57.	Plenary Lecture, Journees Galeniques de Saint-Remy de Provence, Saint-Remy, France, 2006
58.	Plenary Lecture, 2nd International Symposium on Scientific & Regulatory Aspects of Dissolution & Bioequivalence, 2005
59.	Plenary Lecture, 9th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, 2005
60.	Keynote Address, British Pharmaceutical Conference, Manchester, UK, 2005
61.	Doctor of Philosophy, honoris causa, University of Athens, Greece, 2005
62.	Career Achievement Award in Oral Drug Delivery, Controlled Release Society 2004 Annual Meeting & Exposition, 2004
63.	Research Achievement Award in Pharmaceutical Sciences, Pharmaceutical Sciences World Congress 2004, Kyoto, 2004
64.	Opening Plenary Lecture, First Congress of the Portuguese Society for Pharmaceutical Sciences, 2003
65.	ISI Highly Cited Researcher, Institute for Scientific Information, 2003
66.	Invested as a “Member of Honour”, Romanian Academy of Medical Sciences, 2003
67.	Chair, IOM/NRC Committee on Accelerating the Research, Development and Acquisition, of Medical Countermeasures Against Biological Warfare Agents, 2002-2004
68.	Plenary Lecture, 10th International Conference on Pharmaceutical Technology, Florence, Italy, 2002
69.	Invested as a “Miembro Honorario”, Academia de Ciencias Farmacéuticas de Chile, Santiago, Chile, 2002
70.	Plenary Lecture, International Pharmaceutical Technology Symposium 2002, Istanbul, Turkey, 2002
71.	Elected Fellow, American Association of Indian Pharmaceutical Scientists, 2001
72.	Høst-Madsen Medal, International Pharmaceutical Federation, 2001

Publications

Yu Z, Liu W, Wang Z, Chen Y, Yan J, Benet LZ, Zhai S. Is there a possibility that P-glycoprotein reduces reproductive toxicity in males but breast cancer resistance protein does not? Clin Transl Sci. 2024 Oct; 17(10):e70027.

Benet LZ, Sodhi JK. Commentary: Pharmacokinetic Theory Must Consider Published Experimental Data. Drug Metab Dispos. 2024 Aug 14; 52(9):932-938.

Benet LZ, Tiitto MV, Sodhi JK. The potential of developing high hepatic clearance drugs via controlled release: Lessons from Kirchhoff's Laws. J Control Release. 2024 Sep; 373:564-567.

Benet LZ, Sodhi JK. Are all measures of liver Kpuu a function of FH, as determined following oral dosing, or have we made a critical error in defining hepatic drug clearance? Eur J Pharm Sci. 2024 May 01; 196:106753.

Wakuda H, Xiang Y, Sodhi JK, Uemura N, Benet LZ. An Explanation of Why Dose-Corrected Area Under the Curve for Alternate Administration Routes Can Be Greater than for Intravenous Dosing. AAPS J. 2024 01 30; 26(1):22.

Benet LZ. Solubility-Permeability Interplay in Facilitating the Prediction of Drug Disposition Routes, Extent of Absorption, Food Effects, Brain Penetration and Drug Induced Liver Injury Potential. J Pharm Sci. 2023 09; 112(9):2326-2331.

Benet LZ, Sodhi JK. The Uses and Advantages of Kirchhoff's Laws vs. Differential Equations in Pharmacology, Pharmacokinetics, and (Even) Chemistry. AAPS J. 2023 04 10; 25(3):38.

Liu W, Yu Z, Wang Z, Waubant EL, Zhai S, Benet LZ. Using an animal model to predict the effective human dose for oral multiple sclerosis drugs. Clin Transl Sci. 2023 03; 16(3):467-477.

Pachter JA, Dill KA, Sodhi JK, Benet LZ. Review of the application of Kirchhoff's Laws of series and parallel flows to pharmacology: Defining organ clearance. Pharmacol Ther. 2022 Nov; 239:108278.

Bocci G, Oprea TI, Benet LZ. State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References. AAPS J. 2022 02 23; 24(2):37.

Kameyama T, Sodhi JK, Benet LZ. Does Addition of Protein to Hepatocyte or Microsomal In Vitro Incubations Provide a Useful Improvement in In Vitro-In Vivo Extrapolation Predictability? Drug Metab Dispos. 2022 04; 50(4):401-412.

Benet LZ, Sodhi JK. Can In Vitro-In Vivo Extrapolation Be Successful? Recognizing the Incorrect Clearance Assumptions. Clin Pharmacol Ther. 2022 05; 111(5):1022-1035.

Liu S, Sodhi JK, Benet LZ. Analyzing Potential Intestinal Transporter Drug-Drug Interactions: Reevaluating Ticagrelor Interaction Studies. Pharm Res. 2021 Oct; 38(10):1639-1644.

Burmeister Getz E, Carroll KJ, Mielke J, Jones B, Benet LZ. Batch Selection via In Vitro/In Vivo Correlation in Pharmacokinetic Bioequivalence Testing. AAPS PharmSciTech. 2021 Aug 19; 22(7):224.

Bamfo NO, Hosey-Cojocari C, Benet LZ, Remsberg CM. Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans. Pharm Res. 2021 Jul; 38(7):1139-1156.

Xiang Y, Okochi H, Kozachenko I, Sodhi JK, Frassetto LA, Benet LZ. Effects of Single Dose Rifampin on the Pharmacokinetics of Fluvastatin in Healthy Volunteers. Clin Pharmacol Ther. 2021 08; 110(2):480-485.

Benet LZ, Sodhi JK, Makrygiorgos G, Mesbah A. There is Only One Valid Definition of Clearance: Critical Examination of Clearance Concepts Reveals the Potential for Errors in Clinical Drug Dosing Decisions. AAPS J. 2021 05 10; 23(3):67.

Kou W, Sodhi JK, Wu X, Benet LZ. Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption. Pharm Res. 2021 May; 38(5):795-801.

Okochi H, Louie A, Phung N, Zhang K, Tallerico RM, Kuncze K, Spinelli MA, Koss CA, Benet LZ, Gandhi M. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART. Drug Test Anal. 2021 Jul; 13(7):1354-1370.

Benet LZ. Using Individualized Patient Data for Prediction of Population Dosing Recommendations Versus Predictions of Individualized Patient Dosing. J Clin Pharmacol. 2021 06; 61(6):734-735.

Sodhi JK, Benet LZ. Successful and Unsuccessful Prediction of Human Hepatic Clearance for Lead Optimization. J Med Chem. 2021 04 08; 64(7):3546-3559.

Sodhi JK, Huang CH, Benet LZ. Volume of Distribution is Unaffected by Metabolic Drug-Drug Interactions. Clin Pharmacokinet. 2021 02; 60(2):205-222.

Sodhi JK, Liu S, Benet LZ. Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition. Pharm Res. 2020 Sep 29; 37(10):208.

Benet LZ, Sodhi JK. Investigating the Theoretical Basis for In Vitro-In Vivo Extrapolation (IVIVE) in Predicting Drug Metabolic Clearance and Proposing Future Experimental Pathways. AAPS J. 2020 09 10; 22(5):120.

Di L, Artursson P, Avdeef A, Benet LZ, Houston JB, Kansy M, Kerns EH, Lennernäs H, Smith DA, Sugano K. The Critical Role of Passive Permeability in Designing Successful Drugs. ChemMedChem. 2020 10 19; 15(20):1862-1874.

Sodhi JK, Benet LZ. The Necessity of Using Changes in Absorption Time to Implicate Intestinal Transporter Involvement in Oral Drug-Drug Interactions. AAPS J. 2020 08 17; 22(5):111.

Sodhi JK, Benet LZ. A Simple Methodology to Differentiate Changes in Bioavailability From Changes in Clearance Following Oral Dosing of Metabolized Drugs. Clin Pharmacol Ther. 2020 08; 108(2):306-315.

Sodhi JK, Wang HJ, Benet LZ. Are There Any Experimental Perfusion Data that Preferentially Support the Dispersion and Parallel-Tube Models over the Well-Stirred Model of Organ Elimination? Drug Metab Dispos. 2020 07; 48(7):537-543.

Liu W, Yan T, Chen K, Yang L, Benet LZ, Zhai S. Predicting Interactions between Rifampin and Antihypertensive Drugs Using the Biopharmaceutics Drug Disposition Classification System. Pharmacotherapy. 2020 04; 40(4):274-290.

Sodhi JK, Liu S, Benet LZ. Challenging the Relevance of Unbound Tissue-to-Blood Partition Coefficient (Kpuu) on Prediction of Drug-Drug Interactions. Pharm Res. 2020 Mar 25; 37(4):73.

Sun A, Benet LZ. Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis. Pharmacology. 2020; 105(3-4):145-163.

Bocci G, Benet LZ, Oprea TI. Can BDDCS illuminate targets in drug design? Drug Discov Today. 2019 12; 24(12):2299-2306.

Wang HJ, Benet LZ. Protein Binding and Hepatic Clearance: Re-Examining the Discrimination between Models of Hepatic Clearance with Diazepam in the Isolated Perfused Rat Liver Preparation. Drug Metab Dispos. 2019 12; 47(12):1397-1402.

Bowman CM, Benet LZ. In Vitro-In Vivo Inaccuracy: The CYP3A4 Anomaly. Drug Metab Dispos. 2019 12; 47(12):1368-1371.

Surofchy DD, Frassetto LA, Benet LZ. Food, Acid Supplementation and Drug Absorption - a Complicated Gastric Mix: a Randomized Control Trial. Pharm Res. 2019 Sep 04; 36(11):155.

Benet LZ, Bowman CM, Sodhi JK. How Transporters Have Changed Basic Pharmacokinetic Understanding. AAPS J. 2019 09 03; 21(6):103.

Moriya Y, Kogame A, Tagawa Y, Morohashi A, Kondo T, Asahi S, Benet LZ. The Enhancement of Subcutaneous First-Pass Metabolism Causes Nonlinear Pharmacokinetics of TAK-448 after a Single Subcutaneous Administration to Rats. Drug Metab Dispos. 2019 09; 47(9):1004-1012.

Bowman CM, Benet LZ. Interlaboratory Variability in Human Hepatocyte Intrinsic Clearance Values and Trends with Physicochemical Properties. Pharm Res. 2019 May 31; 36(8):113.

Benet LZ, Bowman CM, Koleske ML, Rinaldi CL, Sodhi JK. Understanding drug-drug interaction and pharmacogenomic changes in pharmacokinetics for metabolized drugs. J Pharmacokinet Pharmacodyn. 2019 04; 46(2):155-163.

Bowman CM, Benet LZ. In Vitro-In Vivo Extrapolation and Hepatic Clearance-Dependent Underprediction. J Pharm Sci. 2019 07; 108(7):2500-2504.

Kogame A, Moriya Y, Mori I, Pan L, Morohashi A, Ebihara T, Fukui H, Tagawa Y, Benet LZ. Characterization of Fasiglifam-Related Liver Toxicity in Dogs. Drug Metab Dispos. 2019 05; 47(5):525-534.

Bowman CM, Okochi H, Benet LZ. The Presence of a Transporter-Induced Protein Binding Shift: A New Explanation for Protein-Facilitated Uptake and Improvement for In Vitro-In Vivo Extrapolation. Drug Metab Dispos. 2019 04; 47(4):358-363.

Benet LZ, Jayachandran P, Carroll KJ, Burmeister Getz E. Batch-to-Batch and Within-Subject Variability: What Do We Know and How Do These Variabilities Affect Clinical Pharmacology and Bioequivalence? Clin Pharmacol Ther. 2019 02; 105(2):326-328.

Jayachandran P, Okochi H, Frassetto LA, Park W, Fang L, Zhao L, Benet LZ. Evaluating Within-Subject Variability for Narrow Therapeutic Index Drugs. Clin Pharmacol Ther. 2019 02; 105(2):411-416.

Wolfe AR, Neitz RJ, Burlingame M, Suzuki BM, Lim KC, Scheideler M, Nelson DL, Benet LZ, Caffrey CR. TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling. Int J Parasitol Drugs Drug Resist. 2018 12; 8(3):571-586.

Benet LZ, Bowman CM, Liu S, Sodhi JK. The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analyses. Pharm Res. 2018 Oct 22; 35(12):242.

Hysi PG, Khawaja AP, Menni C, Tamraz B, Wareham N, Khaw KT, Foster PJ, Benet LZ, Spector TD, Hammond CJ. Ascorbic acid metabolites are involved in intraocular pressure control in the general population. Redox Biol. 2019 01; 20:349-353.

Gandhi M, Bacchetti P, Rodrigues WC, Spinelli M, Koss CA, Drain PK, Baeten JM, Mugo NR, Ngure K, Benet LZ, Okochi H, Wang G, Vincent M. Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence. EClinicalMedicine. 2018 Aug-Sep; 2-3:22-28.

Bowman CM, Benet LZ. An examination of protein binding and protein-facilitated uptake relating to in vitro-in vivo extrapolation. Eur J Pharm Sci. 2018 Oct 15; 123:502-514.

Chan R, Benet LZ. Evaluation of the Relevance of DILI Predictive Hypotheses in Early Drug Development: Review of In Vitro Methodologies vs BDDCS Classification. Toxicol Res (Camb). 2018 May 08; 7(3):358-370.

Benet LZ. Predicting Pharmacokinetics/Pharmacodynamics in the Individual Patient: Separating Reality From Hype. J Clin Pharmacol. 2018 Aug; 58(8):979-989.

Chan R, Benet LZ. Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI. Toxicol Sci. 2018 04 01; 162(2):499-508.

Liu W, Guan X, Yu Z, Chen K, Benet L, Zhai S. A Drug-drug Interaction Between Cyclosporine and Nystatin. Clin Ther. 2018 04; 40(4):660-662.

Phung N, Kuncze K, Okochi H, Louie A, Benet LZ, Ofokotun I, Haas DW, Currier JS, Chawana TD, Sheth AN, Bacchetti P, Gandhi M, Horng H. Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2018 Mar 15; 32(5):431-441.

Parasrampuria DA, Benet LZ, Sharma A. Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations. AAPS J. 2018 03 13; 20(3):46.

Park J, Thomas S, Zhong AY, Wolfe AR, Krings G, Terranova-Barberio M, Pawlowska N, Benet LZ, Munster PN. Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer. Sci Rep. 2018 01 08; 8(1):92.

Koss CA, Hosek SG, Bacchetti P, Anderson PL, Liu AY, Horng H, Benet LZ, Kuncze K, Louie A, Saberi P, Wilson CM, Gandhi M. Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States. Clin Infect Dis. 2018 01 06; 66(2):213-219.

Benet LZ, Liu S, Wolfe AR. The Universally Unrecognized Assumption in Predicting Drug Clearance and Organ Extraction Ratio. Clin Pharmacol Ther. 2018 03; 103(3):521-525.

Morrissey KM, Benet LZ, Ware JA. Commentary on: "Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide". Clin Transl Sci. 2017 07; 10(4):240-241.

Benet LZ, Wu HF. Understanding the Potential Interethnic Difference in Rosuvastatin Pharmacokinetics. J Pharm Sci. 2017 09; 106(9):2231-2233.

Noguchi S, Nishimura T, Mukaida S, Benet LZ, Nakashima E, Tomi M. Cellular Uptake of Levocetirizine by Organic Anion Transporter 4. J Pharm Sci. 2017 09; 106(9):2895-2898.

Wu HF, Hristeva N, Chang J, Liang X, Li R, Frassetto L, Benet LZ. Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. J Pharm Sci. 2017 09; 106(9):2751-2757.

Chan R, Benet LZ. Evaluation of DILI Predictive Hypotheses in Early Drug Development. Chem Res Toxicol. 2017 04 17; 30(4):1017-1029.

Koss CA, Bacchetti P, Hillier SL, Livant E, Horng H, Mgodi N, Mirembe BG, Gomez Feliciano K, Horn S, Liu AY, Glidden DV, Grant RM, Benet LZ, Louie A, van der Straten A, Chirenje ZM, Marrazzo JM, Gandhi M. Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. AIDS Res Hum Retroviruses. 2017 08; 33(8):778-783.

Faber KP, Wu HF, Yago MR, Xu X, Kadiyala P, Frassetto LA, Benet LZ. Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption. Pharm Res. 2017 03; 34(3):619-628.

Li J, Larregieu CA, Benet LZ. Classification of natural products as sources of drugs according to the biopharmaceutics drug disposition classification system (BDDCS). Chin J Nat Med. 2016 Dec; 14(12):888-897.

Burmeister Getz E, Carroll KJ, Mielke J, Benet LZ, Jones B. Between-Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial. Clin Pharmacol Ther. 2017 03; 101(3):331-340.

Gandhi M, Glidden DV, Mayer K, Schechter M, Buchbinder S, Grinsztejn B, Hosek S, Casapia M, Guanira J, Bekker LG, Louie A, Horng H, Benet LZ, Liu A, Grant RM. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Lancet HIV. 2016 11; 3(11):e521-e528.

Bowman CM, Benet LZ. Hepatic Clearance Predictions from In Vitro-In Vivo Extrapolation and the Biopharmaceutics Drug Disposition Classification System. Drug Metab Dispos. 2016 11; 44(11):1731-1735.

Benet LZ. 2016 Remington Honor Medal Address: Science for the profession. J Am Pharm Assoc (2003). 2016 Jul-Aug; 56(4):365-8.

Mave V, Chandanwale A, Kinikar A, Khadse S, Kagal A, Gupte N, Suryavanshi N, Nimkar S, Koli H, Khwaja S, Bharadwaj R, Joshi S, Horng H, Benet LZ, Ramachandran G, Dooley KE, Gupta A, Gandhi M. Isoniazid hair concentrations in children with tuberculosis: a proof of concept study. Int J Tuberc Lung Dis. 2016 06; 20(6):844-7.

Benet LZ, Hosey CM, Ursu O, Oprea TI. BDDCS, the Rule of 5 and drugability. Adv Drug Deliv Rev. 2016 06 01; 101:89-98.

Burmeister Getz E, Carroll KJ, Jones B, Benet LZ. Batch-to-batch pharmacokinetic variability confounds current bioequivalence regulations: A dry powder inhaler randomized clinical trial. Clin Pharmacol Ther. 2016 Sep; 100(3):223-31.

Chan R, Wei CY, Chen YT, Benet LZ. Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage. AAPS J. 2016 05; 18(3):757-66.

Zheng Y, Chen X, Benet LZ. Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain. Clin Pharmacokinet. 2016 Feb; 55(2):143-67.

Hosey CM, Chan R, Benet LZ. BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs. AAPS J. 2016 Jan; 18(1):251-60.

Garrison KL, Sahin S, Benet LZ. Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS. J Pharm Sci. 2015 Sep; 104(9):3229-35.

Hosey CM, Benet LZ. Predicting the extent of metabolism using in vitro permeability rate measurements and in silico permeability rate predictions. Mol Pharm. 2015 May 04; 12(5):1456-66.

Zheng Y, Benet LZ, Okochi H, Chen X. pH Dependent but not P-gp Dependent Bidirectional Transport Study of S-propranolol: The Importance of Passive Diffusion. Pharm Res. 2015 Aug; 32(8):2516-26.

Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83.

Parasrampuria DA, Benet LZ. Inclusion of placebos and blinding for ascending dose first-in-human studies and other underpowered phase 1 studies has not been justified and on balance is not useful. Basic Clin Pharmacol Toxicol. 2015 Jul; 117(1):44-51.

Yago MR, Frymoyer A, Benet LZ, Smelick GS, Frassetto LA, Ding X, Dean B, Salphati L, Budha N, Jin JY, Dresser MJ, Ware JA. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. AAPS J. 2014 Nov; 16(6):1358-65.

Hosey CM, Broccatelli F, Benet LZ. Predicting when biliary excretion of parent drug is a major route of elimination in humans. AAPS J. 2014 Sep; 16(5):1085-96.

Larregieu CA, Benet LZ. Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery. Mol Pharm. 2014 Apr 07; 11(4):1335-44.

Frassetto LA, Tan-Tam CC, Barin B, Browne M, Wolfe AR, Stock PG, Roland M, Benet LZ. Best single time point correlations with AUC for cyclosporine and tacrolimus in HIV-infected kidney and liver transplant recipients. Transplantation. 2014 Mar 27; 97(6):702-7.

Zhu S, Rezvani M, Harbell J, Mattis AN, Wolfe AR, Benet LZ, Willenbring H, Ding S. Mouse liver repopulation with hepatocytes generated from human fibroblasts. Nature. 2014 Apr 03; 508(7494):93-7.

Smelick GS, Heffron TP, Chu L, Dean B, West DA, Duvall SL, Lum BL, Budha N, Holden SN, Benet LZ, Frymoyer A, Dresser MJ, Ware JA. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm. 2013 Nov 04; 10(11):4055-62.

Estudante M, Maya M, Morais JG, Soveral G, Benet LZ. Effect of P-glycoprotein on the rat intestinal permeability and metabolism of the BDDCS class 1 drug verapamil. Mol Pharm. 2013 Nov 04; 10(11):4038-45.

Frassetto L, Floren L, Barin B, Browne M, Wolfe A, Roland M, Stock P, Carlson L, Christians U, Benet L. Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. Biopharm Drug Dispos. 2013 Nov; 34(8):442-51.

Yago MR, Frymoyer AR, Smelick GS, Frassetto LA, Budha NR, Dresser MJ, Ware JA, Benet LZ. Gastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria. Mol Pharm. 2013 Nov 04; 10(11):4032-7.

Horng H, Benet LZ. The nonenzymatic reactivity of the acyl-linked metabolites of mefenamic acid toward amino and thiol functional group bionucleophiles. Drug Metab Dispos. 2013 Nov; 41(11):1923-33.

Horng H, Benet LZ. Characterization of the acyl-adenylate linked metabolite of mefenamic Acid. Chem Res Toxicol. 2013 Mar 18; 26(3):465-76.

Silber BM, Rao S, Fife KL, Gallardo-Godoy A, Renslo AR, Dalvie DK, Giles K, Freyman Y, Elepano M, Gever JR, Li Z, Jacobson MP, Huang Y, Benet LZ, Prusiner SB. Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice. Pharm Res. 2013 Apr; 30(4):932-50.

Larregieu CA, Benet LZ. Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements. AAPS J. 2013 Apr; 15(2):483-97.

Benet LZ. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J Pharm Sci. 2013 Jan; 102(1):34-42.

Benet LZ. A step closer to personalized chemotherapy: consideration of the influence of genetic variation in hepatic uptake transporters on the metabolism of CYP3A substrates. Clin Pharmacol Ther. 2012 Nov; 92(5):551-2.

Estudante M, Morais JG, Soveral G, Benet LZ. Intestinal drug transporters: an overview. Adv Drug Deliv Rev. 2013 Oct; 65(10):1340-56.

Budha NR, Frymoyer A, Smelick GS, Jin JY, Yago MR, Dresser MJ, Holden SN, Benet LZ, Ware JA. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther. 2012 Aug; 92(2):203-13.

Benet LZ. Benet L Z and Galeazzi R L: noncompartmental determination of the steady-state volume of distribution, J Pharm Sci 68, 1071-1074, 1979--the backstory. AAPS J. 2012 Jun; 14(2):164-7.

Liu W, Okochi H, Benet LZ, Zhai SD. Sotalol permeability in cultured-cell, rat intestine, and PAMPA system. Pharm Res. 2012 Jul; 29(7):1768-74.

Broccatelli F, Cruciani G, Benet LZ, Oprea TI. BDDCS class prediction for new molecular entities. Mol Pharm. 2012 Mar 05; 9(3):570-80.

Broccatelli F, Larregieu CA, Cruciani G, Oprea TI, Benet LZ. Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan; 64(1):95-109.

Frymoyer A, Guglielmo BJ, Wilson SD, Scarpace SB, Benet LZ, Hersh AL. Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations. Pharmacotherapy. 2011 Sep; 31(9):871-6.

Grover A, Frassetto LA, Benet LZ, Chakkera HA. Pharmacokinetic differences corroborate observed low tacrolimus dosage in Native American renal transplant patients. Drug Metab Dispos. 2011 Nov; 39(11):2017-9.

Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J. 2011 Dec; 13(4):519-47.

Rowland M, Benet LZ. Lead PK commentary: predicting human pharmacokinetics. J Pharm Sci. 2011 Oct; 100(10):4047-9.

Terasaki T, Sugiyama Y, Benet LZ. Professor Akira Tsuji: scientist, educator, and leader. J Pharm Sci. 2011 Sep; 100(9):3541-6.

Reyes M, Benet LZ. Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics. J Pharm Sci. 2011 Sep; 100(9):3831-42.

Grover A, Benet LZ. Intermittent drug dosing intervals guided by the operational multiple dosing half lives for predictable plasma accumulation and fluctuation. J Pharmacokinet Pharmacodyn. 2011 Jun; 38(3):369-83.

Chen ML, Amidon GL, Benet LZ, Lennernas H, Yu LX. The BCS, BDDCS, and regulatory guidances. Pharm Res. 2011 Jul; 28(7):1774-8.

Park MS, Okochi H, Benet LZ. Is Ciprofloxacin a Substrate of P-glycoprotein? Arch Drug Inf. 2011 Mar; 4(1):1-9.

Aarons L, Benet LZ. Founding figures of pharmacokinetics: tribute to Malcolm Rowland. J Pharmacokinet Pharmacodyn. 2010 Dec; 37(6):525-7.

Benet LZ. Clearance (née Rowland) concepts: a downdate and an update. J Pharmacokinet Pharmacodyn. 2010 Dec; 37(6):529-39.

Gottschalk S, Cummins CL, Leibfritz D, Christians U, Benet LZ, Serkova NJ. Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism. Neurotoxicology. 2011 Jan; 32(1):50-7.

Frymoyer A, Shugarts S, Browne M, Wu AH, Frassetto L, Benet LZ. Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers. Clin Pharmacol Ther. 2010 Oct; 88(4):540-7.

Benet LZ, Larregieu CA. The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted. Clin Pharmacol Ther. 2010 Sep; 88(3):405-7.

International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. Membrane transporters in drug development. Nat Rev Drug Discov. 2010 Mar; 9(3):215-36.

Frymoyer A, Hersh AL, Coralic Z, Benet LZ, Joseph Guglielmo B. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation. Clin Ther. 2010 Mar; 32(3):534-42.

Sun H, Frassetto LA, Huang Y, Benet LZ. Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin Pharmacol Ther. 2010 Apr; 87(4):465-72.

Grillo MP, Wait JC, Tadano Lohr M, Khera S, Benet LZ. Stereoselective flunoxaprofen-S-acyl-glutathione thioester formation mediated by acyl-CoA formation in rat hepatocytes. Drug Metab Dispos. 2010 Jan; 38(1):133-42.

Benet LZ. Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System. Basic Clin Pharmacol Toxicol. 2010 Mar; 106(3):162-7.

de Souza J, Benet LZ, Huang Y, Storpirtis S. Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. J Pharm Sci. 2009 Nov; 98(11):4413-9.

Benet LZ. The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm. 2009 Nov-Dec; 6(6):1631-43.

Benet LZ. A Holy Grail of clinical pharmacology: prediction of drug pharmacokinetics and pharmacodynamics in the individual patient. Clin Pharmacol Ther. 2009 Aug; 86(2):133-4.

Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res. 2009 Sep; 26(9):2039-54.

Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009 May; 28(5):398-402.

Grover A, Benet LZ. Effects of drug transporters on volume of distribution. AAPS J. 2009 Jun; 11(2):250-61.

Gandhi M, Benet LZ, Bacchetti P, Kalinowski A, Anastos K, Wolfe AR, Young M, Cohen M, Minkoff H, Gange SJ, Greenblatt RM, Women's Interagency HIV Study. Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2009 Apr 15; 50(5):482-91.

Sahin S, Benet LZ. The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res. 2008 Dec; 25(12):2869-77.

Zheng HX, Huang Y, Frassetto LA, Benet LZ. Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther. 2009 Jan; 85(1):78-85.

Monera TG, Wolfe AR, Maponga CC, Benet LZ, Guglielmo J. Moringa oleifera leaf extracts inhibit 6beta-hydroxylation of testosterone by CYP3A4. J Infect Dev Ctries. 2008 Oct 01; 2(5):379-83.

Grillo MP, Hua F, March KL, Benet LZ, Knutson CG, Ware JA. Gamma-glutamyltranspeptidase-mediated degradation of diclofenac-S-acyl-glutathione in vitro and in vivo in rat. Chem Res Toxicol. 2008 Oct; 21(10):1933-8.

Benet LZ, Amidon GL, Barends DM, Lennernäs H, Polli JE, Shah VP, Stavchansky SA, Yu LX. The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res. 2008 Mar; 25(3):483-8.

Li C, Grillo MP, Badagnani I, Fife KL, Benet LZ. Differential effects of fibrates on the metabolic activation of 2-phenylpropionic acid in rats. Drug Metab Dispos. 2008 Apr; 36(4):682-7.

Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, Freise CE, Benet LZ, Ascher NL, Roberts JP, Murphy B, Keller MJ, Olthoff KM, Blumberg EA, Brayman KL, Bartlett ST, Davis CE, McCune JM, Bredt BM, Stablein DM, Stock PG. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008 Feb; 8(2):355-65.

Custodio JM, Wu CY, Benet LZ. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008 Mar 17; 60(6):717-33.

Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, Carlson L, Benet LZ. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant. 2007 Dec; 7(12):2816-20.

Boernsen KO, Egge-Jacobsen W, Inverardi B, Strom T, Streit F, Schiebel HM, Benet LZ, Christians U. Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus. J Mass Spectrom. 2007 Jun; 42(6):793-802.

Frassetto LA, Poon S, Tsourounis C, Valera C, Benet LZ. Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin Pharmacol Ther. 2007 Jun; 81(6):828-32.

Olsen J, Li C, Skonberg C, Bjørnsdottir I, Sidenius U, Benet LZ, Hansen SH. Studies on the metabolism of tolmetin to the chemically reactive acyl-coenzyme A thioester intermediate in rats. Drug Metab Dispos. 2007 May; 35(5):758-64.

Lau YY, Huang Y, Frassetto L, Benet LZ. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007 Feb; 81(2):194-204.

Lam JL, Shugarts SB, Okochi H, Benet LZ. Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J Pharmacol Exp Ther. 2006 Nov; 319(2):864-70.

Lam JL, Okochi H, Huang Y, Benet LZ. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab Dispos. 2006 Aug; 34(8):1336-44.

Lau YY, Okochi H, Huang Y, Benet LZ. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos. 2006 Jul; 34(7):1175-81.

Huang Y, Okochi H, May BC, Legname G, Prusiner SB, Benet LZ, Guglielmo BJ, Lin ET. Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos. 2006 Jul; 34(7):1136-44.

Huang Y, Sun H, Frassetto L, Benet LZ, Lin ET. Liquid chromatographic tandem mass spectrometric assay for the uremic toxin 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid in human plasma. Rapid Commun Mass Spectrom. 2006; 20(10):1611-4.

Barr SC, Warner KL, Kornreic BG, Piscitelli J, Wolfe A, Benet L, McKerrow JH. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob Agents Chemother. 2005 Dec; 49(12):5160-1.

Olsen J, Li C, Bjørnsdottir I, Sidenius U, Hansen SH, Benet LZ. In vitro and in vivo studies on acyl-coenzyme A-dependent bioactivation of zomepirac in rats. Chem Res Toxicol. 2005 Nov; 18(11):1729-36.

Lau YY, Okochi H, Huang Y, Benet LZ. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther. 2006 Feb; 316(2):762-71.

Chang JH, Benet LZ. Glucuronidation and the transport of the glucuronide metabolites in LLC-PK1 cells. Mol Pharm. 2005 Sep-Oct; 2(5):428-34.

Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006 Jan; 109(1-2):1-11.

Wetmore JB, Benet LZ, Kleinstuck D, Frassetto L. Effects of short-term alendronate on bone mineral density in haemodialysis patients. Nephrology (Carlton). 2005 Aug; 10(4):393-9.

Frassetto L, Baluom M, Jacobsen W, Christians U, Roland ME, Stock PG, Carlson L, Benet LZ. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation. 2005 Jul 15; 80(1):13-7.

Putnam WS, Woo JM, Huang Y, Benet LZ. Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. J Clin Pharmacol. 2005 Apr; 45(4):411-21.

Benet LZ. There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found. Mol Interv. 2005 Apr; 5(2):79-83.

Benet L. Basic pharmacological interactions and how they may impact on one another. J Acquir Immune Defic Syndr. 2005 Mar; 38 Suppl 1:S22-3.

Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005 Jan; 22(1):11-23.

Mohri K, Okada K, Benet LZ. Stereoselective taurine conjugation of (R)-benoxaprofen enantiomer in rats: in vivo and in vitro studies using rat hepatic mitochondria and microsomes. Pharm Res. 2005 Jan; 22(1):79-85.

Lam JL, Benet LZ. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos. 2004 Nov; 32(11):1311-6.

Egge-Jacobsen W, Unger M, Niemann CU, Baluom M, Hirai S, Benet LZ, Christians U. Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors. Ther Drug Monit. 2004 Oct; 26(5):546-62.

Ikeno F, Lyons J, Kaneda H, Baluom M, Benet LZ, Rezaee M. Novel percutaneous adventitial drug delivery system for regional vascular treatment. Catheter Cardiovasc Interv. 2004 Oct; 63(2):222-30.

Christians U, Gottschalk S, Miljus J, Hainz C, Benet LZ, Leibfritz D, Serkova N. Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors. Br J Pharmacol. 2004 Oct; 143(3):388-96.

Sun H, Huang Y, Frassetto L, Benet LZ. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos. 2004 Nov; 32(11):1239-46.

Kim WY, Benet LZ. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul; 21(7):1284-93.

Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm. 2004 Jun 11; 277(1-2):3-9.

Frassetto LA, Benet LZ. Pharmacogenomics and transplantation: where are we? Am J Transplant. 2004 Jun; 4(6):843.

Serkova NJ, Christians U, Benet LZ. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv. 2004 Apr; 4(2):97-107.

Lau YY, Wu CY, Okochi H, Benet LZ. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J Pharmacol Exp Ther. 2004 Mar; 308(3):1040-5.

Wu CY, Benet LZ. Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. Drug Metab Dispos. 2003 Nov; 31(11):1292-5.

Cummins CL, Jacobsen W, Christians U, Benet LZ. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther. 2004 Jan; 308(1):143-55.

Benet LZ, Cummins CL, Wu CY. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab. 2003 Oct; 4(5):393-8.

Li C, Olurinde MO, Hodges LM, Grillo MP, Benet LZ. Covalent binding of 2-phenylpropionyl-S-acyl-CoA thioester to tissue proteins in vitro. Drug Metab Dispos. 2003 Jun; 31(6):727-30.

Li C, Grillo MP, Benet LZ. In vivo mechanistic studies on the metabolic activation of 2-phenylpropionic acid in rat. J Pharmacol Exp Ther. 2003 Apr; 305(1):250-6.

Cummins CL, Salphati L, Reid MJ, Benet LZ. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J Pharmacol Exp Ther. 2003 Apr; 305(1):306-14.

Li C, Grillo MP, Benet LZ. In vitro studies on the chemical reactivity of 2,4-dichlorophenoxyacetyl-S-acyl-CoA thioester. Toxicol Appl Pharmacol. 2003 Mar 01; 187(2):101-9.

Frassetto L, Thai T, Aggarwal AM, Bucher P, Jacobsen W, Christians U, Benet LZ, Floren LC. Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. Drug Metab Pharmacokinet. 2003; 18(2):114-20.

Hebert MF, Wacher VJ, Roberts JP, Benet LZ. Pharmacokinetics of cyclosporine pre- and post-liver transplantation. J Clin Pharmacol. 2003 Jan; 43(1):38-42.

Putnam WS, Ramanathan S, Pan L, Takahashi LH, Benet LZ. Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells. J Pharm Sci. 2002 Dec; 91(12):2622-35.

Unger M, Holzgrabe U, Jacobsen W, Cummins C, Benet LZ. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med. 2002 Dec; 68(12):1055-8.

Li C, Benet LZ, Grillo MP. Enantioselective covalent binding of 2-phenylpropionic Acid to protein in vitro in rat hepatocytes. Chem Res Toxicol. 2002 Nov; 15(11):1480-7.

Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther. 2002 Nov; 72(5):474-89.

Li C, Benet LZ, Grillo MP. Studies on the chemical reactivity of 2-phenylpropionic acid 1-O-acyl glucuronide and S-acyl-CoA thioester metabolites. Chem Res Toxicol. 2002 Oct; 15(10):1309-17.

Niemann CU, Saeed M, Akbari H, Jacobsen W, Benet LZ, Christians U, Serkova N. Close association between the reduction in myocardial energy metabolism and infarct size: dose-response assessment of cyclosporine. J Pharmacol Exp Ther. 2002 Sep; 302(3):1123-8.

Susanto M, Benet LZ. Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport? Pharm Res. 2002 Apr; 19(4):457-62.

Flanagan SD, Takahashi LH, Liu X, Benet LZ. Contributions of saturable active secretion, passive transcellular, and paracellular diffusion to the overall transport of furosemide across adenocarcinoma (Caco-2) cells. J Pharm Sci. 2002 Apr; 91(4):1169-77.

Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002 Mar; 71(3):115-21.

Serkova N, Donohoe P, Gottschalk S, Hainz C, Niemann CU, Bickler PE, Litt L, Benet LZ, Leibfritz D, Christians U. Comparison of the effects of cyclosporin a on the metabolism of perfused rat brain slices during normoxia and hypoxia. J Cereb Blood Flow Metab. 2002 Mar; 22(3):342-52.

Parasrampuria DA, Lantz MV, Birnbaum JL, Vincenti FG, Benet LZ. Effect of calcineurin inhibitor therapy on P-gp expression and function in lymphocytes of renal transplant patients: a preliminary evaluation. J Clin Pharmacol. 2002 Mar; 42(3):304-11.

Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. 2002 Mar; 300(3):1036-45.

Unger M, Jacobsen W, Holzgrabe U, Benet LZ. Quantitative liquid chromatography-mass spectrometry determination of isatin in urine using automated on-line extraction. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Feb 15; 767(2):245-53.

Putnam WS, Pan L, Tsutsui K, Takahashi L, Benet LZ. Comparison of bidirectional cephalexin transport across MDCK and caco-2 cell monolayers: interactions with peptide transporters. Pharm Res. 2002 Jan; 19(1):27-33.

Flanagan SD, Cummins CL, Susanto M, Liu X, Takahashi LH, Benet LZ. Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). Pharmacology. 2002; 64(3):126-34.

Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002; 41(11):813-51.

Grillo MP, Benet LZ. Studies on the reactivity of clofibryl-S-acyl-CoA thioester with glutathione in vitro. Drug Metab Dispos. 2002 Jan; 30(1):55-62.

Tsunoda SM, Harris RZ, Christians U, Velez RL, Freeman RB, Benet LZ, Warshaw A. Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther. 2001 Nov; 70(5):462-7.

Benet LZ, Cummins CL. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev. 2001 Oct 01; 50 Suppl 1:S3-11.

Grillo MP, Chiellini G, Tonelli M, Benet LZ. Effect of alpha-fluorination of valproic acid on valproyl-S-acyl-CoA formation in vivo in rats. Drug Metab Dispos. 2001 Sep; 29(9):1210-5.

Cummins CL, Mangravite LM, Benet LZ. Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1, and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Pharm Res. 2001 Aug; 18(8):1102-9.

Grillo MP, Benet LZ. Interaction of gamma-glutamyltranspeptidase with clofibryl-S-acyl-glutathione in vitro and in vivo in rat. Chem Res Toxicol. 2001 Aug; 14(8):1033-40.

Serkova N, Jacobsen W, Niemann CU, Litt L, Benet LZ, Leibfritz D, Christians U. Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br J Pharmacol. 2001 Jul; 133(6):875-85.

Kuhn B, Jacobsen W, Christians U, Benet LZ, Kollman PA. Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. J Med Chem. 2001 Jun 07; 44(12):2027-34.

Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev. 2001 Mar 01; 46(1-3):89-102.

Jacobsen W, Serkova N, Hausen B, Morris RE, Benet LZ, Christians U. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc. 2001 Feb-Mar; 33(1-2):514-5.

Sawamoto T, Van Gelder T, Christians U, Okamura N, Jacobsen W, Benet L. Membrane transport of mycophenolate mofetil and its active metabolite, mycophenolic acid in MDCK and MDR1-MDCK cell monolayers. J Heart Lung Transplant. 2001 Feb; 20(2):234-235.

Parasrampuria DA, Lantz MV, Benet LZ. A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (P-gp) function. Pharm Res. 2001 Jan; 18(1):39-44.

Qiu Y, Benet LZ, Burlingame AL. Identification of hepatic protein targets of the reactive metabolites of the non-hepatotoxic regioisomer of acetaminophen, 3'-hydroxyacetanilide, in the mouse in vivo using two-dimensional gel electrophoresis and mass spectrometry. Adv Exp Med Biol. 2001; 500:663-73.

Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet. 2001; 40(3):159-68.

Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, Benet LZ, Christians U. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther. 2001 Jan; 69(1):24-31.

Boni JR, Korth-Bradley JM, Richards LS, Chiang ST, Hicks DR, Benet LZ. Chiral bioequivalence: effect of absorption rate on racemic etodolac. Clin Pharmacokinet. 2000 Dec; 39(6):459-69.

Jacobsen W, Christians U, Benet LZ. In vitro evaluation of the disposition of A novel cysteine protease inhibitor. Drug Metab Dispos. 2000 Nov; 28(11):1343-51.

Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000 Nov; 28(11):1369-78.

Christians U, Jacobsen W, Serkova N, Benet LZ, Vidal C, Sewing KF, Manns MP, Kirchner GI. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B Biomed Sci Appl. 2000 Oct 01; 748(1):41-53.

Serkova N, Hausen B, Berry GJ, Jacobsen W, Benet LZ, Morris RE, Christians U. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. J Pharmacol Exp Ther. 2000 Jul; 294(1):323-32.

Christians U, First MR, Benet LZ. Recommendations for bioequivalence testing of cyclosporine generics revisited. Ther Drug Monit. 2000 Jun; 22(3):330-45.

Soldner A, Benet LZ, Mutschler E, Christians U. Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol. 2000 Mar; 129(6):1235-43.

Serkova N, Litt L, Leibfritz D, Hausen B, Morris RE, James TL, Benet LZ, Christians U. The novel immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates. Br J Pharmacol. 2000 Feb; 129(3):485-92.

Hausen B, Ikonen T, Briffa N, Berry GJ, Christians U, Robbins RC, Hook L, Serkova N, Benet LZ, Schuler W, Morris RE. Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. Transplantation. 2000 Jan 15; 69(1):76-86.

Jäger W, Correia MA, Bornheim LM, Mahnke A, Hanstein WG, Xue L, Benet LZ. Ethynylestradiol-mediated induction of hepatic CYP3A9 in female rats: implication for cyclosporine metabolism. Drug Metab Dispos. 1999 Dec; 27(12):1505-11.

Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release. 1999 Nov 01; 62(1-2):25-31.

Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Baner K, Benet LZ, Sewing KF, Christians U. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. J Pharmacol Exp Ther. 1999 Oct; 291(1):131-9.

Mizuma T, McDonagh AF, Lin ET, Benet LZ. Photoinduced covalent binding of frusemide and frusemide glucuronide to human serum albumin. Br J Clin Pharmacol. 1999 Jul; 48(1):79-87.

Serkova N, Litt L, James TL, Sadée W, Leibfritz D, Benet LZ, Christians U. Evaluation of individual and combined neurotoxicity of the immunosuppressants cyclosporine and sirolimus by in vitro multinuclear NMR spectroscopy. J Pharmacol Exp Ther. 1999 May; 289(2):800-6.

Benet LZ. Relevance of pharmacokinetics in narrow therapeutic index drugs. Transplant Proc. 1999 May; 31(3):1642-4; discussion 1675-84.

Benet LZ. Understanding bioequivalence testing. Transplant Proc. 1999 May; 31(3A Suppl):7S-9S.

Hausen B, Boeke K, Berry GJ, Segarra I, Benet LZ, Christians U, Morris RE. Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. Transplantation. 1999 Apr 15; 67(7):956-62.

Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ. Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res. 1999 Apr; 16(4):478-85.

Mizuma T, Benet LZ, Lin ET. Interaction of human serum albumin with furosemide glucuronide: a role of albumin in isomerization, hydrolysis, reversible binding and irreversible binding of a 1-O-acyl glucuronide metabolite. Biopharm Drug Dispos. 1999 Apr; 20(3):131-6.

Zhang Y, Guo X, Lin ET, Benet LZ. In vitro biotransformation of a novel antimalarial cysteine protease inhibitor in human liver microsomes. Pharmacology. 1999 Mar; 58(3):147-59.

Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing KF, Christians U. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos. 1999 Feb; 27(2):173-9.

Salphati L, Benet LZ. Metabolism of digoxin and digoxigenin digitoxosides in rat liver microsomes: involvement of cytochrome P4503A. Xenobiotica. 1999 Feb; 29(2):171-85.

Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, Mayo RR, Turgeon DK, Bailey DG, Fontana RJ, Wrighton SA. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos. 1999 Feb; 27(2):161-6.

Flanagan SD, Benet LZ. Net secretion of furosemide is subject to indomethacin inhibition, as observed in Caco-2 monolayers and excised rat jejunum. Pharm Res. 1999 Feb; 16(2):221-24.

Segarra I, Brazelton TR, Guterman N, Hausen B, Jacobsen W, Morris RE, Benet LZ, Christians U. Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl)rapamycin. J Chromatogr B Biomed Sci Appl. 1998 Dec 11; 720(1-2):179-87.

Tsunoda SM, Harris RZ, Mroczkowski PJ, Benet LZ. Preliminary evaluation of progestins as inducers of cytochrome P450 3A4 activity in postmenopausal women. J Clin Pharmacol. 1998 Dec; 38(12):1137-43.

Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci. 1998 Nov; 87(11):1322-30.

Mizuma T, Benet LZ, Lin ET. High-performance liquid chromatographic determination and identification of acyl migration and photodegradation products of furosemide 1-O-acyl glucuronide. J Chromatogr B Biomed Sci Appl. 1998 Oct 23; 718(1):153-62.

Zhang Y, Benet LZ. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers. Pharm Res. 1998 Oct; 15(10):1520-4.

Zhang Y, Hsieh Y, Izumi T, Lin ET, Benet LZ. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. J Pharmacol Exp Ther. 1998 Oct; 287(1):246-52.

Benet LZ. Impact of intraindividual variability of drugs on therapeutic outcomes: lessons from outside transplantation. Transplant Proc. 1998 Aug; 30(5):1650-1.

Qiu Y, Benet LZ, Burlingame AL. Identification of the hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry. J Biol Chem. 1998 Jul 10; 273(28):17940-53.

Salphati L, Benet LZ. Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology. 1998 Jun; 56(6):308-13.

Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing KF, Christians U. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther. 1998 Jun; 285(3):1104-12.

Zhang Y, Guo X, Lin ET, Benet LZ. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. Drug Metab Dispos. 1998 Apr; 26(4):360-6.

Mohri K, Okada K, Benet LZ. Stereoselective metabolism of benoxaprofen in rats. Biliary excretion of benoxaprofen taurine conjugate and glucuronide. Drug Metab Dispos. 1998 Apr; 26(4):332-7.

Jang GR, Benet LZ. Antiprogestin-mediated inactivation of cytochrome P450 3A4. Pharmacology. 1998 Mar; 56(3):150-7.

Qiu Y, Burlingame AL, Benet LZ. Mechanisms for covalent binding of benoxaprofen glucuronide to human serum albumin. Studies By tandem mass spectrometry. Drug Metab Dispos. 1998 Mar; 26(3):246-56.

Salphati L, Benet LZ. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem Pharmacol. 1998 Feb 15; 55(4):387-95.

Mizuma T, Benet LZ, Lin ET. Preparative chromatography of furosemide 1-O-acyl-glucuronide from urine using micronized amberiite XAD-2 and its application to other 1-O-acyl-glucuronides. Prep Biochem Biotechnol. 1998 Feb; 28(1):37-47.

Jang GR, Benet LZ. Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use. J Pharmacokinet Biopharm. 1997 Dec; 25(6):647-72.

Jang GR, Benet LZ. Cytochrome P4503A4-mediated N-demethylation of the antiprogestins lilopristone and onapristone. Drug Metab Dispos. 1997 Oct; 25(10):1119-22.

Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997 Sep; 62(3):248-60.

Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Hebert MF. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther. 1997 Jul; 62(1):41-9.

Yuan R, Sumi M, Benet LZ. Investigation of aortic CYP3A bioactivation of nitroglycerin in vivo. J Pharmacol Exp Ther. 1997 Jun; 281(3):1499-505.

Wu ST, Benet LZ, Lin ET. Determination of amiprilose in human plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr B Biomed Sci Appl. 1997 Apr 25; 692(1):149-56.

Wu ST, Chang YP, Gee WL, Benet LZ, Lin ET. Stereoselective high-performance liquid chromatography determination of propranolol and 4-hydroxypropranolol in human plasma after pre-column derivatization. J Chromatogr B Biomed Sci Appl. 1997 Apr 25; 692(1):133-40.

Shah VP, Yacobi A, Barr WH, Benet LZ, Breimer D, Dobrinska MR, Endrenyi L, Fairweather W, Gillespie W, Gonzalez MA, Hooper J, Jackson A, Lesko LJ, Midha KK, Noonan PK, Patnaik R, Williams RL. Evaluation of orally administered highly variable drugs and drug formulations. Pharm Res. 1996 Nov; 13(11):1590-4.

Sambol NC, Chiang J, O'Conner M, Liu CY, Lin ET, Goodman AM, Benet LZ, Karam JH. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol. 1996 Nov; 36(11):1012-21.

Sambol NC, Brookes LG, Chiang J, Goodman AM, Lin ET, Liu CY, Benet LZ. Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br J Clin Pharmacol. 1996 Oct; 42(4):510-2.

Benet LZ. Morality play. Science. 1996 Sep 27; 273(5283):1782; author reply 1784-5.

Jang GR, Wrighton SA, Benet LZ. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. Biochem Pharmacol. 1996 Sep 13; 52(5):753-61.

Haj-Yehia AI, Benet LZ. In vivo depletion of free thiols does not account for nitroglycerin-induced tolerance: a thiol-nitrate interaction hypothesis as an alternative explanation for nitroglycerin activity and tolerance. J Pharmacol Exp Ther. 1996 Sep; 278(3):1296-305.

Iwaki M, Ogiso T, Hayashi H, Tanino T, Benet LZ. Acute dose-dependent disposition studies of nicotinic acid in rats. Drug Metab Dispos. 1996 Jul; 24(7):773-9.

Kenkare SR, Benet LZ. Tolerance to nitroglycerin in rabbit aorta. Investigating the involvement of the mu isozyme of glutathione S-transferases. Biochem Pharmacol. 1996 May 17; 51(10):1357-63.

Berg-Candolfi M, Candolfi E, Benet LZ. Suppression of intestinal and hepatic cytochrome P4503A in murine Toxoplasma infection. Effects of N-acetylcysteine and N(G)-monomethyl-L-arginine on the hepatic suppression. Xenobiotica. 1996 Apr; 26(4):381-94.

Harris RZ, Tsunoda SM, Mroczkowski P, Wong H, Benet LZ. The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin Pharmacol Ther. 1996 Apr; 59(4):429-35.

Jaeger W, Benet LZ, Bornheim LM. Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica. 1996 Mar; 26(3):275-84.

Chang T, Benet LZ, Hebert MF. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 1996 Mar; 59(3):297-303.

Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, Wacher VJ. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther. 1995 Nov; 58(5):492-7.

Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol. 1995 Nov; 35(11):1094-102.

Zia-Amirhosseini P, Ding A, Burlingame AL, McDonagh AF, Benet LZ. Synthesis and mass-spectrometric characterization of human serum albumins modified by covalent binding of two non-steroidal anti-inflammatory drugs: tolmetin and zomepirac. Biochem J. 1995 Oct 15; 311 ( Pt 2):431-5.

d'Uscio CH, Aweeka FT, Prueksaritanont T, Tomlanovich SJ, Gupta SK, Lantz MV, Gambertoglio JG, Garovoy MR, Benet LZ. Immunopharmacodynamic studies of cyclosporine in patients awaiting renal transplantation. J Clin Pharmacol. 1995 Oct; 35(10):967-73.

Iwaki M, Bischer A, Nguyen AC, McDonagh AF, Benet LZ. Stereoselective disposition of naproxen glucuronide in the rat. Drug Metab Dispos. 1995 Oct; 23(10):1099-103.

Bischer A, Iwaki M, Zia-Amirhosseini P, Benet LZ. Stereoselective reversible binding properties of the glucuronide conjugates of fenoprofen enantiomers to human serum albumin. Drug Metab Dispos. 1995 Sep; 23(9):900-3.

Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos. 1995 Aug; 23(8):825-31.

Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995 Aug; 50(2):222-39.

Bischer A, Zia-Amirhosseini P, Iwaki M, McDonagh AF, Benet LZ. Stereoselective binding properties of naproxen glucuronide diastereomers to proteins. J Pharmacokinet Biopharm. 1995 Aug; 23(4):379-95.

Benet LZ, Goyan JE. Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy. 1995 Jul-Aug; 15(4):433-40.

Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995 Jul; 13(3):129-34.

Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther. 1995 Jul; 58(1):15-9.

Wacher VJ, Liu T, Roberts JP, Ascher NL, Benet LZ. Time course of cyclosporine and ist motabolites in blood, liver and spleen of naive Lewis rats: comparison with preliminary data obtained in transplanted animals. Biopharm Drug Dispos. 1995 May; 16(4):303-12.

Haj-Yehia AI, Benet LZ. 2-(4-N-maleimidophenyl)-6-methoxybenzofuran: a superior derivatizing agent for fluorimetric determination of aliphatic thiols by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1995 Apr 07; 666(1):45-53.

Haj-Yehia AI, Benet LZ. Dissociation of tissue thiols content from nitroglycerin-induced cyclic-3',5'-guanosine monophosphate and the state of tolerance: in vivo experiments in rats. J Pharmacol Exp Ther. 1995 Apr; 273(1):94-100.

Benet LZ, Zia-Amirhosseini P. Basic principles of pharmacokinetics. Toxicol Pathol. 1995 Mar-Apr; 23(2):115-23.

Sekikawa H, Yagi N, Oda K, Kenmotsu H, Takada M, Chen HF, Lin ET, Benet LZ. Biliary excretion of furosemide glucuronide in rabbits. Biol Pharm Bull. 1995 Mar; 18(3):447-53.

Ding A, Zia-Amirhosseini P, McDonagh AF, Burlingame AL, Benet LZ. Reactivity of tolmetin glucuronide with human serum albumin. Identification of binding sites and mechanisms of reaction by tandem mass spectrometry. Drug Metab Dispos. 1995 Mar; 23(3):369-76.

Sekikawa H, Yagi N, Lin ET, Benet LZ. Apparent intramolecular acyl migration and hydrolysis of furosemide glucuronide in aqueous solution. Biol Pharm Bull. 1995 Jan; 18(1):134-9.

Haj-Yehia AI, Benet LZ. Determination of aliphatic thiols by fluorometric high-performance liquid chromatography after precolumn derivatization with 2-(4-N-maleimidophenyl)-6-methylbenzothiazole. Pharm Res. 1995 Jan; 12(1):155-60.

Zia-Amirhosseini PZ, Harris RZ, Brodsky FM, Benet LZ. Hypersensitivity to nonsteroidal anti-inflammatory drugs. Nat Med. 1995 Jan; 1(1):2-4.

Kenkare SR, Han C, Benet LZ. Correlation of the response to nitroglycerin in rabbit aorta with the activity of the mu class glutathione S-transferase. Biochem Pharmacol. 1994 Dec 16; 48(12):2231-5.

Iwaki M, Ogiso T, Hayashi H, Lin ET, Benet LZ. Simultaneous measurement of nicotinic acid and its major metabolite, nicotinuric acid in urine using high-performance liquid chromatography: application of solid-liquid extraction. J Chromatogr B Biomed Appl. 1994 Nov 04; 661(1):154-8.

Perotti BY, Prueksaritanont T, Benet LZ. HPLC assay for FK 506 and two metabolites in isolated rat hepatocytes and rat liver microsomes. Pharm Res. 1994 Jun; 11(6):844-7.

Ojingwa JC, Spahn-Langguth H, Benet LZ. Irreversible binding of tolmetin to macromolecules via its glucuronide: binding to blood constituents, tissue homogenates and subcellular fractions in vitro. Xenobiotica. 1994 Jun; 24(6):495-506.

Gustavson LE, Benet LZ. Menopause: pharmacodynamics and pharmacokinetics. Exp Gerontol. 1994 May-Aug; 29(3-4):437-44.

Han C, Jung P, Sanders SW, Lin ET, Benet LZ. Pharmacokinetics of nitroglycerin and its four metabolites during nitroglycerin transdermal administration. Biopharm Drug Dispos. 1994 Mar; 15(2):179-83.

Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Clin Pharmacol. 1994 Feb; 34(2):111-9.

Ojingwa JC, Spahn-Langguth H, Benet LZ. Reversible binding of tolmetin, zomepirac, and their glucuronide conjugates to human serum albumin and plasma. J Pharmacokinet Biopharm. 1994 Feb; 22(1):19-40.

Zia-Amirhosseini P, Spahn-Langguth H, Benet LZ. Bioactivation by glucuronide-conjugate formation. Adv Pharmacol. 1994; 27:385-97.

Zia-Amirhosseini P, Ojingwa JC, Spahn-Langguth H, McDonagh AF, Benet LZ. Enhanced covalent binding of tolmetin to proteins in humans after multiple dosing. Clin Pharmacol Ther. 1994 Jan; 55(1):21-7.

Perotti BY, Okudaira N, Prueksaritanont T, Benet LZ. FK 506 metabolism in male and female rat liver microsomes. Drug Metab Dispos. 1994 Jan-Feb; 22(1):85-9.

Benet LZ. Pharmacokinetic profile of etodolac in special populations. Eur J Rheumatol Inflamm. 1994; 14(1):15-8.

Aweeka FT, Tomlanovich SJ, Prueksaritanont T, Gupta SK, Benet LZ. Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. J Clin Pharmacol. 1994 Jan; 34(1):60-7.

Benet LZ, Zech K. Pharmacokinetics--a relevant factor for the choice of a drug? Aliment Pharmacol Ther. 1994; 8 Suppl 1:25-32.

Munafo A, Hyneck ML, Benet LZ. Pharmacokinetics and irreversible binding of tolmetin and its glucuronic acid esters in the elderly. Pharmacology. 1993 Nov; 47(5):309-17.

Lee FW, Salmonson T, Benet LZ. Pharmacokinetics and pharmacodynamics of nitroglycerin and its dinitrate metabolites in conscious dogs: intravenous infusion studies. J Pharmacokinet Biopharm. 1993 Oct; 21(5):533-50.

Gumbleton M, Benet LZ. Simultaneous pharmacodynamic modeling of the non-steady-state effects of three oral doses of 1,3-glyceryl dinitrate upon blood pressure in healthy volunteers. J Pharmacokinet Biopharm. 1993 Oct; 21(5):515-32.

Kenkare SR, Benet LZ. Effect of ethacrynic acid, a glutathione-S-transferase inhibitor, on nitroglycerin-mediated cGMP elevation and vasorelaxation of rabbit aortic strips. Biochem Pharmacol. 1993 Jul 20; 46(2):279-84.

Prueksaritanont T, Correia MA, Rettie AE, Swinney DC, Thomas PE, Benet LZ. Cyclosporine metabolism by rat liver microsomes. Evidence for involvement of enzyme(s) other than cytochromes P-450 3A. Drug Metab Dispos. 1993 Jul-Aug; 21(4):730-7.

Gupta SK, Hwang SS, Benet LZ, Gumbleton M. Interpretation and utilization of effect and concentration data collected in an in vivo pharmacokinetic and in vitro pharmacodynamic study. Pharm Res. 1993 Jun; 10(6):889-94.

Ding A, Ojingwa JC, McDonagh AF, Burlingame AL, Benet LZ. Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry. Proc Natl Acad Sci U S A. 1993 May 01; 90(9):3797-801.

Spahn-Langguth H, Benet LZ. Microsomal acyl glucuronidation: enzyme-kinetic studies with labile glucuronides. Pharmacology. 1993 May; 46(5):268-73.

Lee FW, Hu J, Metzler CH, Benet LZ. Nitroglycerin dinitrate metabolites do not affect the pharmacokinetics and pharmacodynamics of nitroglycerin in the dog: a preliminary report. J Pharmacokinet Biopharm. 1993 Apr; 21(2):163-73.

Benet LZ. New techniques in drug metabolism and clinical pharmacology/pharmacokinetics. Am Biotechnol Lab. 1993 Feb; 11(2):44-7.

Mayer S, Mutschler E, Benet LZ, Sphahn-Langguth H. In vitro and in vivo irreversible plasma protein binding of beclobric acid enantiomers. Chirality. 1993; 5(3):120-5.

Benet LZ. Pharmacokinetics of sustained-release etodolac. Rheumatol Int. 1993; 13(2 Suppl):S3-5.

Benet LZ, Spahn-Langguth H, Iwakawa S, Volland C, Mizuma T, Mayer S, Mutschler E, Lin ET. Predictability of the covalent binding of acidic drugs in man. Life Sci. 1993; 53(8):PL141-6.

Haefeli WE, Gumbleton M, Benet LZ, Hoffman BB, Blaschke TF. Comparison of vasodilatory responses to nitroglycerin and its dinitrate metabolites in human veins. Clin Pharmacol Ther. 1992 Dec; 52(6):590-6.

Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther. 1992 Nov; 52(5):453-7.

Lau DT, Chan EK, Benet LZ. Glutathione S-transferase-mediated metabolism of glyceryl trinitrate in subcellular fractions of bovine coronary arteries. Pharm Res. 1992 Nov; 9(11):1460-4.

Cahalan MK, Hashimoto Y, Aizawa K, Verotta D, Ionescu P, Balea M, Eger EI, Benet LZ, Ehrenfeld WK, Goldstone J. Elderly, conscious patients have an accentuated hypotensive response to nitroglycerin. Anesthesiology. 1992 Oct; 77(4):646-55.

Han C, Gumbleton M, Lau DT, Benet LZ. Improved gas chromatographic assay for the simultaneous determination of nitroglycerin and its mono- and dinitrate metabolites. J Chromatogr. 1992 Sep 02; 579(2):237-45.

Prueksaritanont T, Hoener BA, Benet LZ. Effects of low-density lipoprotein and ethinyl estradiol on cyclosporine metabolism in isolated rat liver perfusions. Drug Metab Dispos. 1992 Jul-Aug; 20(4):547-52.

Lau DT, Benet LZ. Effects of sulfobromophthalein and ethacrynic acid on glyceryl trinitrate relaxation. Biochem Pharmacol. 1992 May 28; 43(10):2247-54.

Prueksaritanont T, Koike M, Hoener BA, Benet LZ. Transport and metabolism of cyclosporine in isolated rat hepatocytes. The effects of lipids. Biochem Pharmacol. 1992 May 08; 43(9):1997-2006.

Higo N, Hinz RS, Lau DT, Benet LZ, Guy RH. Cutaneous metabolism of nitroglycerin in vitro. II. Effects of skin condition and penetration enhancement. Pharm Res. 1992 Mar; 9(3):303-6.

Higo N, Hinz RS, Lau DT, Benet LZ, Guy RH. Cutaneous metabolism of nitroglycerin in vitro. I. Homogenized versus intact skin. Pharm Res. 1992 Feb; 9(2):187-90.

Spahn-Langguth H, Benet LZ. Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev. 1992; 24(1):5-47.

Hale VG, Benet LZ. The interconversion of prednisone and prednisolone in human and rabbit organs in vitro is a function of tissue integrity. Pharmacology. 1992; 44(5):273-82.

Volland C, Sun H, Dammeyer J, Benet LZ. Stereoselective degradation of the fenoprofen acyl glucuronide enantiomers and irreversible binding to plasma protein. Drug Metab Dispos. 1991 Nov-Dec; 19(6):1080-6.

Hale VG, Aizawa K, Sheiner LB, Benet LZ. Disposition of prednisone and prednisolone in the perfused rabbit liver: modeling hepatic metabolic processes. J Pharmacokinet Biopharm. 1991 Oct; 19(5):597-614.

Kikkoji T, Gumbleton M, Higo N, Guy RH, Benet LZ. Percutaneous penetration kinetics of nitroglycerin and its dinitrate metabolites across hairless mouse skin in vitro. Pharm Res. 1991 Oct; 8(10):1231-7.

Iwakawa S, Spahn H, Benet LZ, Lin ET. Stereoselective disposition of carprofen, flunoxaprofen, and naproxen in rats. Drug Metab Dispos. 1991 Sep-Oct; 19(5):853-7.

Hammarlund-Udenaes M, Benet LZ. Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. Biopharm Drug Dispos. 1991 Aug-Sep; 12(6):467-77.

Nakashima E, Lau DT, Benet LZ. Variable glyceryl dinitrate formation following infusions of glyceryl trinitrate at different vascular sites in the rat. Pharm Res. 1991 Jul; 8(7):877-82.

Williams RL, Thakker KM, John V, Lin ET, Liang-Gee W, Benet LZ. Nitroglycerin absorption from transdermal systems: formulation effects and metabolite concentrations. Pharm Res. 1991 Jun; 8(6):744-9.

Iwakawa S, He XW, Hashimoto S, Volland C, Benet LZ, Lin ET. Stereoselective disposition of ketoprofen in rats. Drug Metab Dispos. 1991 May-Jun; 19(3):717-8.

Gumbleton M, Benet LZ. Drug metabolism and laboratory anesthetic protocols in the rat: examination of antipyrine pharmacokinetics. Pharm Res. 1991 Apr; 8(4):544-6.

Lau DT, Gumbleton M, Labisch C, Benet LZ. Pharmacokinetic studies of the nitroglycerin metabolites, 1,2- and 1,3- glyceryl dinitrates, in the rat. Biopharm Drug Dispos. 1991 Apr; 12(3):215-22.

Benet LZ. Rho Chi Lecture. Ideals and innovation: drugs, generics, the FDA, and the pharmacist. DICP. 1991 Apr; 25(4):427-30.

Gumbleton M, Benet LZ. Pharmacological activity of the dinitrate metabolites of nitroglycerin following their oral administration to healthy volunteers. Br J Clin Pharmacol. 1991 Feb; 31(2):211-3.

Volland C, Benet LZ. In vitro enantioselective glucuronidation of fenoprofen. Pharmacology. 1991; 43(2):53-60.

Hale VG, Benet LZ. Prednisolone and prednisone exhibit linear extraction in the perfused rabbit liver. Drug Metab Dispos. 1991 Jan-Feb; 19(1):87-93.

Benet LZ. Safety and pharmacokinetics: colloidal bismuth subcitrate. Scand J Gastroenterol Suppl. 1991; 185:29-35.

Volland C, Sun H, Benet LZ. Stereoselective analysis of fenoprofen and its metabolites. J Chromatogr. 1990 Dec 14; 534:127-38.

Lee FW, Salmonson T, Metzler CH, Benet LZ. Pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its two dinitrate metabolites in conscious dogs. J Pharmacol Exp Ther. 1990 Dec; 255(3):1222-9.

Smith PC, Benet LZ, McDonagh AF. Covalent binding of zomepirac glucuronide to proteins: evidence for a Schiff base mechanism. Drug Metab Dispos. 1990 Sep-Oct; 18(5):639-44.

Skelley JP, Amidon GL, Barr WH, Benet LZ, Carter JE, Robinson JR, Shah VP, Yacobi A. Report of the workshop on in vitro and in vivo testing and correlation for oral controlled/modified-release dosage forms. J Pharm Sci. 1990 Sep; 79(9):849-54.

Manfro RC, Pohanka E, Tomlanovich SJ, Benet LZ, Salvatierra O, Garovoy MR. Determination of soluble IL-2 receptors in kidney graft recipients--a 6-month follow-up. Transplant Proc. 1990 Aug; 22(4):1861-2.

Gupta SK, Manfro RC, Tomlanovich SJ, Gambertoglio JG, Garovoy MR, Benet LZ. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J Clin Pharmacol. 1990 Jul; 30(7):643-53.

Lau DT, Benet LZ. Nitroglycerin metabolism in subcellular fractions of rabbit liver. Dose dependency of glyceryl dinitrate formation and possible involvement of multiple isozymes of glutathione S-transferases. Drug Metab Dispos. 1990 May-Jun; 18(3):292-7.

Nakashima E, Rigod JF, Lin ET, Benet LZ. Pharmacokinetics of nitroglycerin and its dinitrate metabolites over a thirtyfold range of oral doses. Clin Pharmacol Ther. 1990 May; 47(5):592-8.

Williams RL, Lin ET, Liang-Gee W, Blume CD, Benet LZ. Absorption and disposition of a new low-dose combination formulation of hydrochlorothiazide and triamterene. Biopharm Drug Dispos. 1990 Apr; 11(3):233-43.

Hamamoto K, Iwamoto HS, Roman CM, Benet LZ, Rudolph AM. Fetal uptake of intraamniotic digoxin in sheep. Pediatr Res. 1990 Mar; 27(3):282-5.

Iwakawa S, Spahn H, Benet LZ, Lin ET. Stereoselective binding of the glucuronide conjugates of carprofen enantiomers to human serum albumin. Biochem Pharmacol. 1990 Mar 01; 39(5):949-53.

Wang LH, Rudolph AM, Benet LZ. Comparative study of acetaminophen disposition in sheep at three developmental stages: the fetal, neonatal and adult periods. Dev Pharmacol Ther. 1990; 14(3):161-79.

Smith PC, McDonagh AF, Benet LZ. Effect of esterase inhibition on the disposition of zomepirac glucuronide and its covalent binding to plasma proteins in the guinea pig. J Pharmacol Exp Ther. 1990 Jan; 252(1):218-24.

Gupta SK, Benet LZ. High-fat meals increase the clearance of cyclosporine. Pharm Res. 1990 Jan; 7(1):46-8.

Munafo A, McDonagh AF, Smith PC, Benet LZ. Irreversible binding of tolmetin glucuronic acid esters to albumin in vitro. Pharm Res. 1990 Jan; 7(1):21-7.

Steffe EM, King JH, Inciardi JF, Flynn NF, Goldstein E, Tonjes TS, Benet LZ. The effect of acetaminophen on zidovudine metabolism in HIV-infected patients. J Acquir Immune Defic Syndr (1988). 1990; 3(7):691-4.

Nakashima E, Benet LZ. An integrated approach to pharmacokinetic analysis for linear mammillary systems in which input and exit may occur in/from any compartment. J Pharmacokinet Biopharm. 1989 Dec; 17(6):673-86.

Ding RW, Kolbe K, Merz B, de Vries J, Weber E, Benet LZ. Pharmacokinetics of nicotinic acid-salicylic acid interaction. Clin Pharmacol Ther. 1989 Dec; 46(6):642-7.

Gupta SK, Benet LZ. Absorption kinetics of cyclosporine in healthy volunteers. Biopharm Drug Dispos. 1989 Nov-Dec; 10(6):591-6.

Watari N, Benet LZ. Determination of mean input time, mean residence time, and steady-state volume of distribution with multiple drug inputs. J Pharmacokinet Biopharm. 1989 Oct; 17(5):593-9.

Teng RL, Benet LZ. Simultaneous measurement of prednisone, prednisolone and 6 beta-hydroxyprednisolone in urine by high-performance liquid chromatography using dexamethasone as the internal standard. J Chromatogr. 1989 Sep 01; 493(2):421-3.

Bois FY, Tozer TN, Zeise L, Benet LZ. Application of clearance concepts to the assessment of exposure to lead in drinking water. Am J Public Health. 1989 Jul; 79(7):827-31.

Iwakawa S, Suganuma T, Lee SF, Spahn H, Benet LZ, Lin ET. Direct determination of diastereomeric carprofen glucuronides in human plasma and urine and preliminary measurements of stereoselective metabolic and renal elimination after oral administration of carprofen in man. Drug Metab Dispos. 1989 Jul-Aug; 17(4):414-9.

Bois FY, Tozer TN, Benet LZ, Zeise L. Lead exposure in children vs adults. Am J Public Health. 1989 Jul; 79(7):904.

Koshida R, Nakashima E, Taniguchi N, Tsuji A, Benet LZ, Ichimura F. Prediction of the distribution volumes of cefazolin and tobramycin in obese children based on physiological pharmacokinetic concepts. Pharm Res. 1989 Jun; 6(6):486-91.

Spahn H, Spahn I, Benet LZ. Probenecid-induced changes in the clearance of carprofen enantiomers: a preliminary study. Clin Pharmacol Ther. 1989 May; 45(5):500-5.

Gloff CA, Benet LZ. Differential effects of the degree of renal damage on p-aminohippuric acid and inulin clearances in rats. J Pharmacokinet Biopharm. 1989 Apr; 17(2):169-77.

Manfro RC, Pohanka E, Tomlanovich S, Benet LZ, Garovoy MR. Cyclosporin A and prednisolone: an additive inhibitory effect of cell proliferation and interleukin-2 production. Transplant Proc. 1989 Feb; 21(1 Pt 2):1457-9.

Lau DT, Benet LZ. Differential formation of dinitrate metabolites from glyceryl trinitrate in subcellular fractions of rabbit liver. Biochem Pharmacol. 1989 Feb 01; 38(3):543-6.

Hammarlund-Udenaes M, Benet LZ. Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update. J Pharmacokinet Biopharm. 1989 Feb; 17(1):1-46.

Spahn H, Iwakawa S, Lin ET, Benet LZ. Procedures to characterize in vivo and in vitro enantioselective glucuronidation properly: studies with benoxaprofen glucuronides. Pharm Res. 1989 Feb; 6(2):125-32.

Spahn H, Spahn I, Pflugmann G, Mutschler E, Benet LZ. Measurement of carprofen enantiomer concentrations in plasma and urine using L-leucinamide as the chiral coupling component. J Chromatogr. 1988 Dec 09; 433:331-8.

Yu DK, Williams RL, Benet LZ, Lin ET, Giesing DH. Pharmacokinetics of nitroglycerin and metabolites in humans following oral dosing. Biopharm Drug Dispos. 1988 Nov-Dec; 9(6):557-65.

Nakashima E, Benet LZ. General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment. J Pharmacokinet Biopharm. 1988 Oct; 16(5):475-92.

Gawienowski M, Benet LZ, Fleckenstein L, Lin ET. Ion-paired liquid chromatographic method for the analysis of blood and plasma for the antimalarial drug halofantrine and its putative mono-debutylated metabolite. J Chromatogr. 1988 Sep 09; 430(2):412-9.

Hyneck ML, Smith PC, Munafo A, McDonagh AF, Benet LZ. Disposition and irreversible plasma protein binding of tolmetin in humans. Clin Pharmacol Ther. 1988 Jul; 44(1):107-14.

Schwartz JB, Upton RA, Lin ET, Williams RL, Benet LZ. Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1988 Jun; 43(6):673-80.

Lee FW, Watari N, Rigod J, Benet LZ. Simultaneous determination of nitroglycerin and its dinitrate metabolites by capillary gas chromatography with electron-capture detection. J Chromatogr. 1988 Apr 29; 426(2):259-66.

Hyneck ML, Munafo A, Benet LZ. Effect of pH on acyl migration and hydrolysis of tolmetin glucuronide. Drug Metab Dispos. 1988 Mar-Apr; 16(2):322-4.

Gloff CA, Mamelok RD, Benet LZ. Organic anion transport by basal-lateral membranes: effect of PAH and furosemide on each other's transport. Pharmacology. 1988; 37(4):268-76.

Hyneck ML, Smith PC, Unseld E, Benet LZ. High-performance liquid chromatographic determination of tolmetin, tolmetin glucuronide and its isomeric conjugates in plasma and urine. J Chromatogr. 1987 Sep 25; 420(2):349-56.

Noonan PK, Benet LZ. Variable glyceryl dinitrate formation as a function of route of nitroglycerin administration. Clin Pharmacol Ther. 1987 Sep; 42(3):273-7.

Williams RL, Mordenti J, Upton RA, Lin ET, Gee WL, Blume CD, Benet LZ. Effects of formulation and food on the absorption of hydrochlorothiazide and triamterene or amiloride from combination diuretic products. Pharm Res. 1987 Aug; 4(4):348-52.

Nakashima E, Noonan PK, Benet LZ. Transdermal bioavailability and first-pass skin metabolism: a preliminary evaluation with nitroglycerin. J Pharmacokinet Biopharm. 1987 Aug; 15(4):423-37.

Ferraiolo BL, Halldin MM, Asscher Y, Akita Y, Melmon KL, Benet LZ, Castagnoli N. Pharmacokinetics and excretion of unique beta-adrenergic agonists. Pharmacology. 1987; 34(2-3):157-66.

Wang LH, Zakim D, Rudolph AM, Benet LZ. Developmental alterations in hepatic UDP-glucuronosyltransferase. A comparison of the kinetic properties of enzymes from adult sheep and fetal lambs. Biochem Pharmacol. 1986 Sep 15; 35(18):3065-70.

Benet LZ. AAPS and pharmaceutical research. Pharm Res. 1986 Aug; 3(4):186.

Williams RL, Thornhill MD, Upton RA, Blume C, Clark TS, Lin E, Benet LZ. Absorption and disposition of two combination formulations of hydrochlorothiazide and triamterene: influence of age and renal function. Clin Pharmacol Ther. 1986 Aug; 40(2):226-32.

Smith PC, Benet LZ. Characterization of the isomeric esters of zomepirac glucuronide by proton NMR. Drug Metab Dispos. 1986 Jul-Aug; 14(4):503-5.

Varughese A, Brater DC, Benet LZ, Lee CS. Ethambutol kinetics in patients with impaired renal function. Am Rev Respir Dis. 1986 Jul; 134(1):34-8.

Wang LH, Rudolph AM, Benet LZ. Pharmacokinetic studies of the disposition of acetaminophen in the sheep maternal-placental-fetal unit. J Pharmacol Exp Ther. 1986 Jul; 238(1):198-205.

Shi RJ, Benet LZ, Lin ET. High-performance liquid chromatographic assay of basic amine drugs in plasma and urine using a silica gel column and an aqueous mobile phase. I. Amiloride. J Chromatogr. 1986 Apr 25; 377:399-404.

Legler UF, Benet LZ. Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives. Clin Pharmacol Ther. 1986 Apr; 39(4):425-9.

Smith PC, McDonagh AF, Benet LZ. Irreversible binding of zomepirac to plasma protein in vitro and in vivo. J Clin Invest. 1986 Mar; 77(3):934-9.

Noonan PK, Benet LZ. The bioavailability of oral nitroglycerin. J Pharm Sci. 1986 Mar; 75(3):241-3.

Sörgel F, Ettinger B, Benet LZ. Metabolic fate and solubility of triamterene--not an explanation for triamterene nephrolithiasis. J Pharm Sci. 1986 Feb; 75(2):129-32.

Gustavson LE, Legler UF, Benet LZ. Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens. J Clin Endocrinol Metab. 1986 Jan; 62(1):234-7.

Legler UF, Benet LZ. The effect of prednisone and hydrocortisone on the plasma protein binding of prednisolone in man. Eur J Clin Pharmacol. 1986; 30(1):51-5.

Gustavson LE, Benet LZ. The macromolecular binding of prednisone in plasma of healthy volunteers including pregnant women and oral contraceptive users. J Pharmacokinet Biopharm. 1985 Dec; 13(6):561-9.

Wang LH, Rudolph AM, Benet LZ. Distribution and fate of acetaminophen conjugates in fetal lambs in utero. J Pharmacol Exp Ther. 1985 Nov; 235(2):302-7.

Sheiner LB, Benet LZ. Premarketing observational studies of population pharmacokinetics of new drugs. Clin Pharmacol Ther. 1985 Nov; 38(5):481-7.

Benet LZ. Mean residence time in the body versus mean residence time in the central compartment. J Pharmacokinet Biopharm. 1985 Oct; 13(5):555-8.

Smith PC, Langendijk PN, Bosso JA, Benet LZ. Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac. Clin Pharmacol Ther. 1985 Aug; 38(2):121-7.

Ferraiolo BL, Benet LZ. Peptides and proteins as drugs. Pharm Res. 1985 Jul; 2(4):151-6.

Noonan PK, Williams RL, Benet LZ. Dose dependent pharmacokinetics of nitroglycerin after multiple intravenous infusions in healthy volunteers. J Pharmacokinet Biopharm. 1985 Apr; 13(2):143-57.

Benet LZ. Pharmacokinetics and metabolism of bepridil. Am J Cardiol. 1985 Mar 15; 55(7):8C-13C.

Tsang SY, Garovoy MR, Benet LZ. Immunosuppressive activity of prednisone and prednisolone and their metabolic interconversion in the mixed lymphocyte reaction. Int J Immunopharmacol. 1985; 7(5):731-7.

Noonan PK, Benet LZ. Incomplete and delayed bioavailability of sublingual nitroglycerin. Am J Cardiol. 1985 Jan 01; 55(1):184-7.

Wang LH, Rudolph AM, Benet LZ. Pharmacokinetics of drugs and metabolites in the maternal-placental-fetal unit: general principles. NIDA Res Monogr. 1985; 60:25-38.

Smith PC, Hasegawa J, Langendijk PN, Benet LZ. Stability of acyl glucuronides in blood, plasma, and urine: studies with zomepirac. Drug Metab Dispos. 1985 Jan-Feb; 13(1):110-2.

Upton RA, Williams RL, Lin ET, Gee WL, Blume CD, Benet LZ. Absence of a significant pharmacokinetic interaction between hydrochlorothiazide and triamterene when coadministered. J Pharmacokinet Biopharm. 1984 Dec; 12(6):575-86.

Blume CD, Williams RL, Upton RA, Lin ET, Benet LZ. Bioequivalence study of a new tablet formulation of triamterene and hydrochlorothiazide. Am J Med. 1984 Nov 05; 77(5A):59-61.

Noonan PK, Kanfer I, Riegelman S, Benet LZ. Determination of picogram nitroglycerin plasma concentrations using capillary gas chromatography with on-column injection. J Pharm Sci. 1984 Jul; 73(7):923-7.

Sörgel F, Lin ET, Hasegawa J, Benet LZ. Liquid chromatographic analysis of triamterene and its major metabolite, hydroxytriamterene sulfate, in blood, plasma, and urine. J Pharm Sci. 1984 Jun; 73(6):831-3.

Langendijk PN, Smith PC, Hasegawa J, Benet LZ. Simultaneous determination of zomepirac and its major metabolite zomepirac glucuronide in human plasma and urine. J Chromatogr. 1984 May 11; 307(2):371-9.

Smith PC, Benet LZ. High-performance liquid chromatographic method for the determination of indomethacin and its two primary metabolites in urine. J Chromatogr. 1984 Mar 09; 306:315-21.

Chiang CW, Benet LZ. Dose-dependent kinetics of probenecid in rhesus monkeys--infusion studies. Pharmacology. 1984; 28(4):181-7.

Benet LZ. Pharmacokinetic parameters: which are necessary to define a drug substance? Eur J Respir Dis Suppl. 1984; 134:45-61.

Meister W, Benowitz NL, Benet LZ. Unchanged absorption of digoxin tablets in patients with cardiac failure. Pharmacology. 1984; 28(2):90-4.

Baughman RA, Sorgel F, Mico BA, Benet LZ. Dose-dependent bioavailability of prazosin in beagle dogs. J Cardiovasc Pharmacol. 1983 Jul-Aug; 5(4):613-7.

Park GB, Kershner RP, Angellotti J, Williams RL, Benet LZ, Edelson J. Oral bioavailability and intravenous pharmacokinetics of amrinone in humans. J Pharm Sci. 1983 Jul; 72(7):817-9.

Lozada F, Frey FJ, Benet LZ. Prednisolone clearance: a possible determinant for glucocorticoid efficacy in patients with oral vesiculo-erosive diseases. J Dent Res. 1983 May; 62(5):575-7.

Benet LZ, Smith DE, Lin ET, Vincenti F, Gambertoglio JG. Furosemide assays and disposition in healthy volunteers and renal transplant patients. Fed Proc. 1983 Apr; 42(6):1695-8.

Baughman RA, Mico BA, Benet LZ. The bioavailability and disposition of tiodazosin levulinate in beagle dogs with a comparison to prazosin hydrochloride. Drug Metab Dispos. 1983 Mar-Apr; 11(2):143-6.

Smith DE, Benet LZ. Biotransformation of furosemide in kidney transplant patients. Eur J Clin Pharmacol. 1983; 24(6):787-90.

Smith DE, Benet LZ. Plasma protein binding of furosemide in kidney transplant patients. J Pharmacokinet Biopharm. 1982 Dec; 10(6):663-74.

Benet LZ, Frey FJ, Amend WJ, Lozada F, Frey BM. Endogenous and exogenous glucocorticoids in cushingoid patients. Drug Intell Clin Pharm. 1982 Nov; 16(11):863-8.

O'Neill PJ, Yorgey KA, Renzi NL, Williams RL, Benet LZ. Disposition of zomepirac sodium in man. J Clin Pharmacol. 1982 Oct; 22(10):470-6.

Hasegawa J, Lin ET, Williams RL, Sörgel F, Benet LZ. Pharmacokinetics of triamterene and its metabolite in man. J Pharmacokinet Biopharm. 1982 Oct; 10(5):507-23.

Legler UF, Frey FJ, Benet LZ. Prednisolone clearance at steady state in man. J Clin Endocrinol Metab. 1982 Oct; 55(4):762-7.

Hasegawa J, Smith PC, Benet LZ. Apparent intramolecular acyl migration of zomepirac glucuronide. Drug Metab Dispos. 1982 Sep-Oct; 10(5):469-73.

Buskin JN, Upton RA, Sörgel F, Williams RL, Lang E, Benet LZ. Specific and sensitive assay of celiprolol in blood, plasma and urine using high-performance liquid chromatography. J Chromatogr. 1982 Jul 09; 230(2):454-60.

Mico BA, Baughman RA, Benet LZ. Determination of tiodazosin in plasma and whole blood by high-performance liquid chromatography. J Chromatogr. 1982 Jun 11; 230(1):203-6.

Frey BM, Frey FJ, Holford NH, Lozada F, Benet LZ. Prednisolone pharmacodynamics assessed by inhibition of the mixed lymphocyte reaction. Transplantation. 1982 Jun; 33(6):578-84.

Williams RL, Blume CD, Lin ET, Holford NH, Benet LZ. Relative bioavailability of chlorthalidone in humans: adverse influence of polyethylene glycol. J Pharm Sci. 1982 May; 71(5):533-5.

Williams RL, Davies RO, Berman RS, Holmes GI, Huber P, Gee WL, Lin ET, Benet LZ. Hydrochlorothiazide pharmacokinetics and pharmacologic effect: the influence of indomethacin. J Clin Pharmacol. 1982 Jan; 22(1):32-41.

Frey FJ, Gambertoglio JG, Frey BM, Benet LZ, Amend WJ. Nonlinear plasma protein binding and haemodialysis clearance of prednisolone. Eur J Clin Pharmacol. 1982; 23(1):65-74.

Williams RL, Furst DE, Mandel HG, Nicoll D, Konikoff JJ, Benet LZ. Effects of indomethacin and carprofen on renal homeostasis in rheumatoid arthritis patients and in healthy individuals. J Clin Pharmacol. 1981 Nov-Dec; 21(11):493-500.

Frey FJ, Amend WJ, Lozada F, Frey BM, Benet LZ. Endogenous hydrocortisone, a possible factor contributing to the genesis of cushingoid habitus in patients on prednisone. J Clin Endocrinol Metab. 1981 Nov; 53(5):1076-80.

Mamelok RD, Macrae DR, Benet LZ, Prusiner SB. Membrane populations of bovine choroid plexus: separation by density gradient centrifugation in modified colloidal silica. J Neurochem. 1981 Sep; 37(3):768-74.

Gustafson JH, Benet LZ. Saturable kinetics of intravenous chlorothiazide in the rhesus monkey. J Pharmacokinet Biopharm. 1981 Aug; 9(4):461-76.

Smith DE, Gambertoglio JG, Vincenti F, Benet LZ. Furosemide kinetics and dynamics after kidney transplant. Clin Pharmacol Ther. 1981 Jul; 30(1):105-13.

Sheiner LB, Benet LZ, Pagliaro LA. A standard approach to compiling clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1981 Feb; 9(1):59-127.

Chiang CW, Benet LZ. Dose-dependent kinetics of probenecid in rhesus monkeys-intravenous bolus studies. Pharmacology. 1981; 23(6):326-36.

Frey FJ, Amend WJ, Lozada F, Frey BM, Holford NH, Benet LZ. Pharmacokinetics of prednisolone and endogenous hydrocortisone levels in cushingoid and non-cushingoid patients. Eur J Clin Pharmacol. 1981; 21(3):235-42.

Frey BM, Frey FJ, Cochrum KC, Benet LZ. Induction kinetics of human suppressor cells in the mixed lymphocyte reaction and influence of prednisolone on their genesis. Cell Immunol. 1980 Nov; 56(1):225-34.

Frey FJ, Frey BM, Greither A, Benet LZ. Prednisolone clearance at steady state in dogs. J Pharmacol Exp Ther. 1980 Nov; 215(2):287-91.

Brater DC, Kaojarern S, Benet LZ, Lin ET, Lockwood T, Morris RC, McSherry EJ, Melmon KL. Renal excretion of pseudoephedrine. Clin Pharmacol Ther. 1980 Nov; 28(5):690-4.

Lin ET, Baughman RA, Benet LZ. High-performance liquid chromatographic determination of prazosin in human plasma, whole blood and urine. J Chromatogr. 1980 Sep 12; 183(3):367-71.

Smith DE, Lin ET, Benet LZ. Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay. Drug Metab Dispos. 1980 Sep-Oct; 8(5):337-42.

Lee CS, Brater DC, Gambertoglio JG, Benet LZ. Disposition kinetics of ethambutol in man. J Pharmacokinet Biopharm. 1980 Aug; 8(4):335-46.

Baughman RA, Arnold S, Benet LZ, Lin ET, Chatterjee K, Williams RL. Altered prazosin pharmacokinetics in congestive heart failure. Eur J Clin Pharmacol. 1980 Jun; 17(6):425-8.

Smith DE, Gee WL, Brater DC, Lin ET, Benet LZ. Preliminary evaluation of furosemide-probenecid interaction in humans. J Pharm Sci. 1980 May; 69(5):571-5.

Lee CS, Marbury TC, Benet LZ. Clearance calculations in hemodialysis: application to blood, plasma, and dialysate measurements for ethambutol. J Pharmacokinet Biopharm. 1980 Feb; 8(1):69-81.

Schmitt JK, Davis JL, Lorenzi M, Benet LZ, Burns A, Karam JH. Inhibition by indomethacin of the glycemic response to arginine in man. Proc Soc Exp Biol Med. 1980 Feb; 163(2):237-9.

Gambertoglio JG, Amend WJ, Benet LZ. Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review. J Pharmacokinet Biopharm. 1980 Feb; 8(1):1-52.

Williams RL, Benet LZ. Drug pharmacokinetics in cardiac and hepatic disease. Annu Rev Pharmacol Toxicol. 1980; 20:389-413.

Till AE, Benet LZ. Renal excretion of pseudoephedrine in the rat. J Pharmacol Exp Ther. 1979 Dec; 211(3):555-60.

Gambertoglio JG, Aziz NS, Lin ET, Grausz H, Naughton JL, Benet LZ. Cefamandole kinetics in uremic patients undergoing hemodialysis. Clin Pharmacol Ther. 1979 Nov; 26(5):592-9.

Ding TL, Benet LZ. Comparative bioavailability and pharmacokinetic studies of azathioprine and 6-mercaptopurine in the rhesus monkey. Drug Metab Dispos. 1979 Nov-Dec; 7(6):373-7.

Frey FJ, Frey BM, Benet LZ. Liquid-chromatographic measurement of endogenous and exogenous glucocorticoids in plasma. Clin Chem. 1979 Nov; 25(11):1944-7.

Arnold SB, Williams RL, Ports TA, Baughman RA, Benet LZ, Parmley WW, Chatterjee K. Attenuation of prazosin effect on cardiac output in chronic heart failure. Ann Intern Med. 1979 Sep; 91(3):345-9.

Benet LZ, Galeazzi RL. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci. 1979 Aug; 68(8):1071-4.

Ding TL, Benet LZ. Determination of 6-mercaptopurine and azathioprine in plasma by high-performance liquid chromatography. J Chromatogr. 1979 Jul 21; 163(3):281-8.

Lin ET, Smith DE, Benet LZ, Hoener BA. High-performance liquid chromatographic assays for furosemide in plasma and urine. J Chromatogr. 1979 Jul 21; 163(3):315-21.

Smith DE, Brater DC, Lin ET, Benet LZ. Attenuation of furosemide's diuretic effect by indomethacin: pharmacokinetic evaluation. J Pharmacokinet Biopharm. 1979 Jun; 7(3):265-74.

Benet LZ. Pharmacokinetics/pharmacodynamics of furosemide in man: a review. J Pharmacokinet Biopharm. 1979 Feb; 7(1):1-27.

Greither A, Goldman S, Edelen JS, Benet LZ, Cohn K. Pharmacokinetics of furosemide in patients with congestive heart failure. Pharmacology. 1979; 19(3):121-31.

Till AE, Benet LZ. Pseudoephedrine pharmacokinetics in the rat using a microanalysis technique. Pharmacology. 1979; 18(6):306-10.

Smith DE, Benet LZ. Relationship between urinary excretion rate, steady-state plasma levels and diuretic response of furosemide in the rat. Pharmacology. 1979; 19(6):301-6.

Benet LZ. Effect of route of administration and distribution on drug action. J Pharmacokinet Biopharm. 1978 Dec; 6(6):559-85.

Ham J, Miller RD, Benet LZ, Matteo RS, Roderick LL. Pharmacokinetics and pharmacodynamics of d-tubocurarine during hypothermia in the cat. Anesthesiology. 1978 Nov; 49(5):324-9.

Lee CS, Benet LZ. Micro and macro GLC determination of ethambutol in biological fluids. J Pharm Sci. 1978 Apr; 67(4):470-3.

Aziz NS, Gambertoglio JG, Lin ET, Grausz H, Benet LZ. Pharmacokinetics of cefamandole using a HPLC assay. J Pharmacokinet Biopharm. 1978 Apr; 6(2):153-64.

Stalker NE, Gambertoglio JG, Fukumitsu CJ, Naughton JL, Benet LZ. Acute massive chloral hydrate intoxication treated with hemodialysis: a clinical pharmacokinetic analysis. J Clin Pharmacol. 1978 Feb-Mar; 18(2-3):136-42.

Barnett G, Lockwood T, Arancibia A, Benet LZ. Ascorbate stimulation of salicylate absorption in isolated rat intestine. J Pharm Sci. 1978 Feb; 67(2):224-6.

Peck CC, Benet LZ. General method for determining macrodissociation constants of polyprotic, amphoteric compounds from solubility measurements. J Pharm Sci. 1978 Jan; 67(1):12-6.

García CR, Siqueiros A, Benet LZ. Oral controlled release preparations. Pharm Acta Helv. 1978; 53(3-4):99-109.

Ding TL, Lin ET, Benet LZ. The reversible biotransformation of N-acetylprocainamide in the rhesus monkey. Arzneimittelforschung. 1978; 28(2):281-3.

Lee CS, Gambertoglio JG, Brater DC, Benet LZ. Kinetics of oral ethambutol in the normal subject. Clin Pharmacol Ther. 1977 Nov; 22(5 Pt 1):615-21.

Lin ET, Brater DC, Benet LZ. Gas-liquid chromatographic determination of pseudoephedrine and norpseudoephedrine in human plasma and urine. J Chromatogr. 1977 Oct 21; 140(3):275-9.

Miller RD, Matteo RS, Benet LZ, Sohn YJ. The pharmacokinetics of d-tubocurarine in man with and without renal failure. J Pharmacol Exp Ther. 1977 Jul; 202(1):1-7.

Ronfeld RA, Benet LZ. Interpretation of plasma concentration-time curves after oral dosing. J Pharm Sci. 1977 Feb; 66(2):178-80.

Lee CS, Benet LZ. Gas-liquid chromatographic determination of ethambutol in plasma and urine of man and monkey. J Chromatogr. 1976 Nov 17; 128(1):188-92.

Galeazzi RL, Benet LZ, Sheiner LB. Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clin Pharmacol Ther. 1976 Sep; 20(3):278-89.

Galeazzi RL, Benet LZ. Inappropriate use of the law of corresponding areas to calculate the time course of absorption for multicompartmental systems. J Pharmacokinet Biopharm. 1976 Feb; 4(1):43-56.

Gustafson JH, Schoenwald RD, Benet LZ. Limitations in interpretation of digoxin adsorption using averaged pharmacological response intensities. J Pharm Sci. 1976 Feb; 65(2):243-7.

Galeazzi RL, Sheiner LB, Lockwood T, Benet LZ. The renal elimination of procainamide. Clin Pharmacol Ther. 1976 Jan; 19(1):55-62.

Pagliaro LA, Benet LZ. Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references. J Pharmacokinet Biopharm. 1975 Oct; 3(5):333-83.

Orr JM, Benet LZ. The effect of fasting on the rate of intestinal drug absorption in rats: preliminary studies. Am J Dig Dis. 1975 Sep; 20(9):858-65.

Till AE, Benet LZ, Kwan KC. An integrated approach to the pharmacokinetic analysis of drug absorption. J Pharmacokinet Biopharm. 1974 Dec; 2(6):525-44.

Gustafson JH, Benet LZ. Biliary excretion kinetics of phenolphthalein glucuronide after intravenous and retrograde biliary administration. J Pharm Pharmacol. 1974 Dec; 26(12):937-44.

Nayak RK, Benet LZ. Use of the unanesthetized rhesus monkey as a model for studying the gastrointestinal absorption of drugs. J Pharmacokinet Biopharm. 1974 Oct; 2(5):417-31.

Rowland M, Benet LZ, Graham GG. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm. 1973 Apr; 1(2):123-36.

Wolfe DL, Forland SC, Benet LZ. Drug transfer across intact rat intestinal mucosa following surgical removal of serosa and muscularis externa. J Pharm Sci. 1973 Feb; 62(2):200-5.

Nelson JA, Moss AA, Goldberg HI, Benet LZ, Amberg J. Gastrointestinal absorption of iopanoic acid. Invest Radiol. 1973 Jan-Feb; 8(1):1-8.

Benet LZ. General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics. J Pharm Sci. 1972 Apr; 61(4):536-41.

Nayak RK, Benet LZ. Drug transfer across rat intestinal musculature after edetic acid treatment. J Pharm Sci. 1971 Oct; 60(10):1508-11.

Benet LZ, Turi JS. Use of general partial fraction theorem for obtaining inverse laplace transforms in pharmacokinetic analysis. J Pharm Sci. 1971 Oct; 60(10):1593-4.

Benet LZ, Orr JM, Turner RH, Webb HS. Effect of buffer constituents and time on drug transfer across in vitro rat intestine. J Pharm Sci. 1971 Feb; 60(2):234-8.

Turner RH, Mehta CS, Benet LZ. Apparent directional permeability coefficients for drug ions: in vitro intestinal perfusion studies. J Pharm Sci. 1970 May; 59(5):590-5.

Rowland M, Benet LZ, Riegelman S. Two-compartment model for a drug and its metabolite: application to acetylsalicylic acid pharmacokinetics. J Pharm Sci. 1970 Mar; 59(3):364-7.

Benet LZ, Ronfeld RA. Volume terms in pharmacokinetics. J Pharm Sci. 1969 May; 58(5):639-41.

Benet LZ, Goyan JE. Potentiometric determination of dissociation constants. J Pharm Sci. 1967 Jun; 56(6):665-80.

Benet LZ, Goyan JE. Thermodynamics of chelation by tetracyclines. J Pharm Sci. 1966 Nov; 55(11):1184-90.

Singh P, Guillory JK, Sokoloski TD, Benet LZ, Bhatia VN. Effect of inert tablet ingredients on drug absorption. I. Effect of polyethylene glycol 4000 on the intestinal absorption of four barbiturates. J Pharm Sci. 1966 Jan; 55(1):63-8.

Benet LZ, Goyan JE. Nonlogarithmic titration curves for the determination of dissociation constants and purity. J Pharm Sci. 1965 Aug; 54(8):1179-82.

Benet LZ, Goyan JE. Determination of the stability constants of tetracycline complexes. J Pharm Sci. 1965 Jul; 54(7):983-7.

Leslie Benet, PhD

Links

Affiliations

Joint appointments

Education programs

UCSF centers, institutes, and research programs

External affiliations

Departmental research area

My research expertise

Professional background

Degrees

Biography

Research keywords

Publications